

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/08213 A1

- (51) International Patent Classification⁷: C07D 295/185, A61K 31/495, A61P 35/00, C07K 5/062, C07F 9/09, C07D 295/088, C07C 217/74, C07D 233/61
- (74) Agents: BRYANT, Tracey et al.; Astrazeneca, Global Intellectual Property, Alderley Park, P.O. Box 272, Mereside, Macclesfield, Cheshire SK10 4GR (GB).
- (21) International Application Number: PCT/GB01/02964
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 4 July 2001 (04.07.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
00401977.4 7 July 2000 (07.07.2000) EP
00401976.6 7 July 2000 (07.07.2000) EP
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): ANGIO-GENE PHARMACEUTICALS LIMITED [GB/GB]; 14 Plowden Park, Aston Rowant, Watlington, Oxfordshire OX9 5SX (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): ARNOULD, Jean, Claude [FR/FR]; Z.I. La Pompelle Boîte postale 1050, 51689 Reims Cedex 2 (FR).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/08213 A1

(54) Title: COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS

(57) Abstract: The invention related to colchinel derivatives of the formula (I): Wherein: R¹, R² and R³ are each independently hydroxy, phosphoryloxy (-OPO₃H₂), C₁₋₄alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R¹, R² and R³ are C₁₋₄alkoxy; A is -CO-, -C(O)O-, -CON(R⁸)- (wherein R⁸ is hydrogen, C₁₋₄alkyl, C₁₋₃alkoxyC₁₋₃alkyl, aminoC₁₋₃alkyl or hydroxyC₁₋₃alkyl); a is an integer from 1 to 4 inclusive; R^a and R^b are independently selected from hydrogen, hydroxy and amino; B is -O-, -CO-, N(R⁹)CO-, -CON(R⁹)-, -N(R⁹)C(O)O-, -N(R⁹)CON(R¹⁰)-, -N(R⁹)SO₂-, -SO₂N(R⁹)- or a direct single bond (wherein R⁹ and R¹⁰ are independently selected from hydrogen, C₁₋₄alkyl, C₁₋₃alkoxyC₁₋₃alkyl, aminoC₁₋₃alkyl and hydroxyC₁₋₃alkyl); b is O or an integer from 1 to 4 inclusive, (provided that when bis O, B is a single direct bond); D is carboxy, sulpho, tetrazolyl, imidazolyl, phosphoryloxy, hydroxy, amino, N-(C₁₋₄alkyl)amino, N,N-di(C₁₋₃alkyl)amino, or of the formula-Y¹(CH₂)_bR¹¹ or -NHCH(R¹²)COOH; [wherein Y¹ is a direct single bond, -O-, -C(O)-, -N(R¹³)C(O)- or -C(O)N(R¹³)- (wherein R¹³ is hydrogen, C₁₋₄alkyl, C₁₋₃alkoxyC₂₋₃alkyl, aminoC₂₋₃alkyl or hydroxyC₂₋₃alkyl); e is O or an integer from 1 to 4 inclusive.

COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS

The present invention relates to vascular damaging agents, to the use of compounds of the invention in the manufacture of medicaments for use in the production of
5 antiangiogenic effects in warm-blooded animals such as humans, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds as active ingredient, to methods for the treatment of disease states associated with angiogenesis and to the use of such compounds as medicaments.

Normal angiogenesis plays an important role in a variety of processes including
10 embryonic development, wound healing and several components of female reproductive function. Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature Medicine 1: 27-31). Formation of new vasculature by angiogenesis is a key
15 pathological feature of several diseases (J. Folkman, New England Journal of Medicine 333, 1757-1763 (1995)). For example, for a solid tumour to grow it must develop its own blood supply upon which it depends critically for the provision of oxygen and nutrients; if this blood supply is mechanically shut off the tumour undergoes necrotic death. Neovascularisation is also a clinical feature of skin lesions in psoriasis, of the invasive pannus in the joints of
20 rheumatoid arthritis patients and of atherosclerotic plaques. Retinal neovascularisation is pathological in macular degeneration and in diabetic retinopathy.

Reversal of neovascularisation by damaging the newly-formed vascular endothelium is expected to have a beneficial therapeutic effect. The present invention is based on the discovery of tricyclic compounds that surprisingly specifically damage newly formed
25 vasculature without affecting the normal, established vascular endothelium of the host species, a property of value in the treatment of disease states associated with angiogenesis such as cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal
30 vessel proliferation.

Compounds of the present invention are colchinel derivatives. Colchinel derivatives for example *N*-acetyl-colchinel are known. Anti-tumour effects have been noted on animal


- 2 -

models (see for example - *Jnl. Natl. Cancer Inst.* 1952, 13, 379-392). However, the effect studied was that of gross damage (haemorrhage, softening and necrosis) and there is no suggestion of treatment of inappropriate angiogenesis by destruction of neovasculature.

It is believed, though this is not limiting on the invention, that the use of compounds of
 5 the invention damages newly-formed vasculature, for example the vasculature of tumours, thus effectively reversing the process of angiogenesis as compared to known anti-angiogenic agents which tend to be less effective once the vasculature has formed.

According to one aspect of the present invention there is provided a compound of the formula (I):

10



(I)

wherein:

R^1 , R^2 and R^3 are each independently hydroxy, phosphoryloxy ($-OPO_3H_2$), C_{1-4} alkoxy or an in
 15 vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R^1 , R^2 and R^3 are C_{1-4} alkoxy;

A is $-CO-$, $-C(O)O-$, $-CON(R^8)-$, $-SO_2-$ or $-SO_2N(R^8)-$ (wherein R^8 is hydrogen, C_{1-4} alkyl, C_{1-3} alkoxy C_{1-3} alkyl, amino C_{1-3} alkyl or hydroxy C_{1-3} alkyl);

a is an integer from 1 to 4 inclusive;

20 R^a and R^b are independently selected from hydrogen, hydroxy and amino;

B is $-O-$, $-CO-$, $-N(R^9)CO-$, $-CON(R^9)-$, $-C(O)O-$, $-N(R^9)-$, $-N(R^9)C(O)O-$, $-N(R^9)CON(R^{10})-$, $-N(R^9)SO_2-$, $-SO_2N(R^9)-$ or a direct single bond (wherein R^9 and R^{10} are independently selected from hydrogen, C_{1-4} alkyl, C_{1-3} alkoxy C_{1-3} alkyl, amino C_{1-3} alkyl and hydroxy C_{1-3} alkyl);

25 b is 0 or an integer from 1 to 4 inclusive, (provided that when b is 0, B is a single direct bond);

D is carboxy, sulpho, tetrazolyl, imidazolyl, phosphoryloxy, hydroxy, amino,

- 3 -

N-(C₁₋₄alkyl)amino, N,N-di(C₁₋₃alkyl)amino or of the formula -Y¹-(CH₂)_cR¹¹ or -NHCH(R¹²)COOH; [wherein Y¹ is a direct single bond, -O-, -C(O)-, -N(R¹³)-, -N(R¹³)C(O)- or -C(O)N(R¹³)- (wherein R¹³ is hydrogen, C₁₋₄alkyl, C₁₋₃alkoxyC₂₋₃alkyl, aminoC₂₋₃alkyl or hydroxyC₂₋₃alkyl); c is 0 or an integer from 1 to 4 inclusive; R¹¹ is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O, S and N, or a 5-6-membered unsaturated or partially unsaturated heteroaryl group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O, S and N, which heterocyclic group or heteroaryl group may bear 1 or 2 substituents selected from:

- 10 oxo, hydroxy, halogeno, C₁₋₄alkyl, C₂₋₄alkanoyl, carbamoyl, N-(C₁₋₄alkyl)carbamoyl, N,N-di-(C₁₋₄alkyl)carbamoyl, hydroxyC₁₋₄alkyl, C₁₋₄alkoxy, cyanoC₁₋₃alkyl, carbamoylC₁₋₃alkyl, carboxyC₁₋₄alkyl, aminoC₁₋₄alkyl, N-C₁₋₄alkylaminoC₁₋₄alkyl, di-N,N-(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl and R¹⁴ (wherein R¹⁴ is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O, S and N, which heterocyclic group is optionally substituted by 1 or 2 substituents selected from:

oxo, hydroxy, halogeno, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkyl and C₁₋₄alkylsulphonylC₁₋₄alkyl);

- 20 R¹² is an amino acid side chain;
 R⁵ is C₁₋₄alkoxy;
 R⁴ and R⁶ are each independently selected from:
 hydrogen, fluoro, nitro, amino, N-C₁₋₄alkylamino, N,N-di-(C₁₋₄alkyl)amino, hydroxy, C₁₋₄alkoxy and C₁₋₄alkyl;
 25 R⁷ is hydrogen, C₁₋₄alkyl, C₁₋₃alkoxyC₁₋₃alkyl, aminoC₁₋₃alkyl or hydroxyC₁₋₃alkyl;
 or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.

In another aspect, the invention relates to a compound of the formula (I) as hereinabove defined or to a pharmaceutically-acceptable salt thereof.

- In this specification the generic term "alkyl" includes both straight-chain and
 30 branched-chain alkyl groups. However references to individual alkyl groups such as "propyl" are specific for the straight-chain version only and references to individual branched-chain

- 4 -

alkyl groups such as "isopropyl" are specific for the branched-chain version only. An analogous convention applies to other generic terms.

R^{12} is an amino acid side chain. This includes side chains from natural and non-natural amino acids and includes the possibility of R^{12} joining to the NH group so as to form a 5 ring as in the amino acid proline. It includes α -amino acids β -amino acids and γ -amino acids. In addition, the amino acids may be L-isomers or D-isomers, but preferably L-isomers. Preferred amino acids include glycine, alanine, valine, leucine, isoleucine, methionine, proline, phenylalanine, tryptophan, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, β -alanine and ornithine.

10 More preferred amino acids include glutamic acid, serine, threonine, arginine, glycine, alanine, β -alanine and lysine. Especially preferred amino acids include glutamic acid, serine, threonine, arginine, alanine and β -alanine. Specific values for R^{12} include hydrogen, C_{1-4} alkyl, C_{1-4} alkylthio C_{1-4} alkyl, hydroxy C_{1-4} alkyl, thio C_{1-4} alkyl, phenyl C_{1-4} alkyl (optionally substituted by hydroxy), guanidino C_{1-4} alkyl, carboxy C_{1-4} alkyl, carbamoyl C_{1-4} alkyl, amino C_{1-4} alkyl and imidazolyl C_{1-4} alkyl and R^{12} forming a pyrrolidinyl ring with the NH group.

15 Preferred values for R^{12} include hydrogen, C_{1-4} alkyl, C_{1-4} alkylthio C_{1-4} alkyl, hydroxy C_{1-4} alkyl, thio C_{1-4} alkyl, guanidino C_{1-4} alkyl, carboxy C_{1-4} alkyl, carbamoyl C_{1-4} alkyl and amino C_{1-4} alkyl.

It is to be understood that, insofar as certain of the compounds of Formula (I) defined above may exist in optically active or racemic forms by virtue of one or more asymmetric carbon atoms, the invention includes in its definition any such optically active or racemic form which possesses vascular damaging activity. The synthesis of optically active forms may be carried out by standard techniques of organic chemistry well known in the art, for example by synthesis from optically active starting materials or by resolution of a racemic form. Similarly, the above-mentioned activity may be evaluated using the standard laboratory techniques referred to hereinafter.

20

25

Suitable values for the generic radicals referred to above include those set out below. Within the present invention it is to be understood that a compound of the formula (I) or a salt thereof may exhibit the phenomenon of tautomerism and that the formulae drawings within this specification can represent only one of the possible tautomeric forms. It is to be understood that the invention encompasses any tautomeric form which has vascular damaging

30

- 5 -

activity and is not to be limited merely to any one tautomeric form utilised within the formulae drawings.

It is also to be understood that certain compounds of the formula (I) and salts thereof can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to
5 be understood that the invention encompasses all such solvated forms which have vascular damaging activity.

The present invention relates to the compounds of formula (I) as hereinbefore defined as well as to the salts thereof. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the
10 compounds of formula (I) and their pharmaceutically acceptable salts. Pharmaceutically acceptable salts of the invention may, for example, include acid addition salts of the compounds of formula (I) as hereinbefore defined which are sufficiently basic to form such salts. Such acid addition salts include for example salts with inorganic or organic acids affording pharmaceutically acceptable anions such as with hydrogen halides (especially
15 hydrochloric or hydrobromic acid of which hydrochloric acid is particularly preferred) or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid. Suitable salts include hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates and tartrates. In addition where the compounds of formula (I) are
20 sufficiently acidic, pharmaceutically acceptable salts may be formed with an inorganic or organic base which affords a pharmaceutically acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt, an alkaline earth metal salt such as a calcium or magnesium salt, an ammonium salt or for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or
25 tris-(2-hydroxyethyl)amine.

Various forms of prodrugs are known in the art. For examples of such prodrug derivatives, see:

- a) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, *et al.* (Academic Press, 1985);
- 30 b) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 "Design and Application of Prodrugs", by H. Bundgaard p. 113-191 (1991);

- 6 -

- c) H. Bundgaard, Advanced Drug Delivery Reviews, **8**, 1-38 (1992);
- d) H. Bundgaard, *et al.*, Journal of Pharmaceutical Sciences, **77**, 285 (1988); and
- e) N. Kakeya, *et al.*, Chem. Pharm. Bull., **32**, 692 (1984).

Examples of such pro-drugs may be used to form in-vivo-cleavable esters of a compound of the Formula (I). An in-vivo-cleavable ester of a compound of the Formula (I) containing a carboxy group is, for example, a pharmaceutically-acceptable ester which is cleaved in the human or animal body to produce the parent acid. Suitable pharmaceutically-acceptable esters for carboxy include C₁₋₆alkoxymethyl esters, for example methoxymethyl; C₁₋₆alkanoyloxymethyl esters, for example pivaloyloxymethyl; phthalidyl esters; C₃₋₈cycloalkoxycarbonyloxy C₁₋₆alkyl esters, for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolan-2-ylmethyl esters, for example 5-methyl-1,3-dioxolan-2-ylmethyl; and C₁₋₆alkoxycarbonyloxyethyl esters, for example 1-methoxycarbonyloxyethyl; and may be formed at any carboxy group in the compounds of this invention.

Suitable values for R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰ or R¹³ or for various substituents on D or R¹⁴ include:

- | | |
|--|---|
| for halogeno | fluoro, chloro, bromo and iodo; |
| for C ₁₋₄ alkyl: | methyl, ethyl, propyl, isopropyl and <u>tert</u> -butyl; |
| for N-C ₁₋₄ alkylamino: | methylamino, ethylamino, propylamino, isopropylamino and butylamino; |
| for N,N-di-[C ₁₋₄ alkyl]amino: | dimethylamino, diethylamino, <u>N</u> -ethyl- <u>N</u> -methylamino and diisopropylamino; |
| for C ₂₋₄ alkanoyl: | acetyl and propionyl; |
| for C ₁₋₄ alkoxy: | methoxy and ethoxy; |
| for cyanoC ₁₋₄ alkyl: | cyanomethyl and 2-cyanoethyl; |
| for <u>N</u> -C ₁₋₄ alkylcarbamoyl: | <u>N</u> -methylcarbamoyl, <u>N</u> -ethylcarbamoyl and <u>N</u> -propylcarbamoyl; |
| for <u>N,N</u> -di-[(C ₁₋₄))alkyl]carbamoyl: | <u>N,N</u> -dimethylcarbamoyl, <u>N</u> -ethyl- <u>N</u> -methylcarbamoyl and <u>N,N</u> -diethylcarbamoyl; |
| for C ₁₋₄ alkylsulphonylalkyl: | methylsulphonylmethyl and ethylsulphonylmethyl; |
| for hydroxyC ₁₋₄ alkyl: | hydroxymethyl, 2-hydroxyethyl, 1-hydroxyethyl and 3-hydroxypropyl as appropriate; |

- 7 -

- for C₁₋₄alkoxyC₁₋₄alkyl: methoxymethyl, ethoxymethyl, 1-methoxyethyl,
2-methoxyethyl, 2-ethoxyethyl and
3-methoxypropyl as appropriate;
- 5 for aminoC₁₋₄alkyl aminomethyl, 2-aminoethyl, 1-aminoethyl and
3-aminopropyl as appropriate;
- for N-C₁₋₄alkylaminoC₁₋₄alkyl: methylaminomethyl, ethylaminomethyl,
1-methylaminoethyl, 2-methylaminoethyl,
10 2-ethylaminoethyl and 3-methylaminopropyl as
appropriate;
- for N,N-di-[C₁₋₄alkyl]aminoC₁₋₄alkyl: dimethylaminomethyl, diethylaminomethyl,
1-dimethylaminoethyl, 2-dimethylaminoethyl and
15 3-dimethylaminopropyl as appropriate;
- for carboxyC₁₋₄alkyl: carboxymethyl, 1-carboxyethyl, 2-carboxyethyl,
3-carboxypropyl and 4-carboxybutyl;
- for carbamoylC₁₋₄alkyl: carbamoylmethyl, 1-carbamoylethyl,
2-carbamoylethyl and 3-carbamoylpropyl;
- 20 for C₁₋₄alkoxyC₁₋₄alkyl methoxymethyl, ethoxyethyl, methoxyethyl, and
methoxypropyl.

Carbamoyl refers to —CONH₂.

Piperazino refers to piperazin-1-yl.

- Examples of 5- or 6-membered saturated heterocyclic groups include pyrrolidinyl,
25 imidazolidinyl, pyrazolidinyl, piperidyl, piperazinyl and morpholinyl.

Examples of 5- or 6-membered unsaturated or partially unsaturated heteroaryl groups
include: imidazolyl, imidazolinyl, pyridyl, pyrrolyl, furanyl, triazolyl, pyrazinyl, pyrazolinyl,
pyrimidinyl, pyridazinyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl and thienyl.

Preferably at least 2 of R¹, R², and R³ are methoxy.

- 30 Preferably R¹, R², and R³ are all C₁₋₄alkoxy.

Most preferably R¹, R², and R³ are all methoxy.

- 8 -

Preferably R^8 is hydrogen, methyl, ethyl, 2-methoxyethyl, 2-aminoethyl or 2-hydroxyethyl.

More preferably R^8 is hydrogen, 2-aminoethyl or 2-hydroxyethyl and most preferably R^8 is hydrogen.

5 Preferably A is $-CO-$, $-C(O)O-$ or $-CON(R^8)-$. Most preferably A is $-C(O)O-$.

Preferably a is 1, 2 or 3 and most preferably a is 2 or 3.

Preferably R^a , and R^b are hydrogen.

Preferably B is $-N(R^9)CO-$, $-CON(R^9)-$, $-C(O)O-$, $-N(R^9)-$, $-N(R^9)C(O)O-$, $N(R^9)CON(R^{10})-$ or a single direct bond.

10 More preferably B is $-CO-$, $-N(R^9)CO-$ or a single direct bond.

Yet more preferably B is $-CO-$ or a single direct bond.

Most preferably B is $-CO-$. In another aspect B is a single direct bond.

Preferably R^9 , and R^{10} are independently selected from hydrogen, methyl, ethyl, 2-methoxyethyl, 2-aminoethyl and 2-hydroxyethyl.

15 More preferably R^9 and R^{10} are independently selected from hydrogen, 2-aminoethyl and 2-hydroxyethyl.

Most preferably R^9 , and R^{10} are hydrogen.

Preferably b is 0, 1 or 2, more preferably b is 0 or 1 and most preferably b is 0.

Preferably R^{11} is a 5 or 6 membered saturated heterocyclic ring containing 1 or 2 ring
20 heteroatoms selected from N and O.

More preferably R^{11} is a 6 membered saturated heterocyclic ring containing 1 or 2 ring heteroatoms selected from N and O.

Further preferably R^{11} contains at least 1 ring nitrogen atom.

Further preferably R^{11} is piperazinyl, morpholinyl or piperidinyl, each of which is
25 linked via a ring carbon or nitrogen ring atom and each ring is optionally substituted by 1 or 2 of the substituents mentioned above for R^{11} .

Further preferably R^{11} is linked via a ring nitrogen atom.

Most preferably R^{11} is piperazino or morpholino, each ring being optionally substituted by 1 or 2 of the substituents mentioned hereinabove for R^{11} .

30 The saturated heterocyclic ring may be substituted on ring carbon or ring nitrogen atoms, providing this does not result in quaternisation.

- 9 -

Preferred substituents for the saturated heterocyclic ring in R^{11} include C_{1-4} alkyl, C_{2-4} alkanoyl, carbamoyl, cyano C_{1-3} alkyl, hydroxy C_{1-3} alkyl, carboxy C_{1-3} alkyl and amino C_{1-3} alkyl.

More preferred substituents for the saturated heterocyclic ring in R^{11} include C_{1-3} alkyl,
5 C_{2-3} alkanoyl, carbamoyl and hydroxy C_{2-3} alkyl.

Yet more preferred substituents for the saturated heterocyclic ring in R^{11} include methyl, acetyl, carbamoyl and 2-hydroxyethyl.

The most preferred substituents for the saturated heterocyclic ring include methyl, acetyl and carbamoyl.

10 Preferably the saturated heterocyclic ring in R^{11} is unsubstituted or substituted by 1 substituent.

When the saturated heterocyclic ring in R^{11} is morpholino, preferably it is unsubstituted. When the saturated heterocyclic ring in R^{11} is piperazino, preferably it is unsubstituted or substituted by 1 substituent on a ring nitrogen atom.

15 Preferably Y^1 is -CONH - or -NHCO -.

Preferably c is 0, 1 or 2.

More preferably c is 0.

Preferred values for R^{11} include morpholino, 4-methylpiperazin-1-yl and 4-acetylpiperazin-1-yl.

20 Preferably R^{14} is morpholino or piperazin-1-yl, each optionally substituted by 1 or 2 substituents selected from C_{1-3} alkyl, hydroxy C_{2-3} alkyl, C_{1-3} alkoxy and C_{1-3} alkoxy C_{1-3} alkyl.

More preferably R^{14} is morpholino, or piperazin-1-yl unsubstituted or substituted by methyl.

Preferably D is carboxy, phosphoryloxy, hydroxy, amino, N- C_{1-4} alkylamino,
25 N,N-di(C_{1-4} alkyl)amino or of the formula $-Y^1(CH_2)_cR^{11}$ wherein Y^1 , c and R^{11} are as hereinabove defined.

More preferably D is carboxy phosphoryloxy, hydroxy, amino or of the formula $-Y^1-(CH_2)_cR^{11}$ wherein Y^1 , c and R^{11} are as hereinabove defined.

More preferably D is phosphoryloxy, amino or of the formula $-Y^1-(CH_2)_cR^{11}$ wherein
30 Y^1 , c and R^{11} are as hereinabove defined.

- 10 -

Yet more preferably D is phosphoyloxy, amino or of the formula $-Y^1-(CH_2)_cR^{11}$ wherein Y^1 and c are as hereinabove defined and R^{11} is morpholino, imidazolyl, or piperazinyl, which heterocyclic group may bear one or more substituents as defined above.

Yet more preferably D is phosphoyloxy, amino or of the formula $-Y^1-(CH_2)_cR^{11}$ 5 wherein Y^1 and c are as hereinabove defined and R^{11} is morpholino, imidazolyl, 4-methylpiperazin-1-yl or 4-acetylpiperazin-1-yl.

Yet even more preferably D is phosphoyloxy, amino or of the formula $-Y^1-(CH_2)_cR^{11}$ wherein Y^1 is a direct single bond and c is 0 and R^{11} is morpholino, imidazol-1-yl, 4-methylpiperazin-1-yl or 4-acetylpiperazin-1-yl.

10 Preferably R^5 is methoxy.

Preferably R^4 and R^6 are independently selected from hydrogen, hydroxy, C_{1-3} alkoxy, and C_{1-3} alkyl.

More preferably at least one of R^4 and R^6 is hydrogen.

Most preferably R^4 and R^6 are both hydrogen.

15 Preferably R^7 is hydrogen or methyl. Most preferably R^7 is hydrogen.

A preferred class of compound is of the formula (I) wherein:

R^1 , R^2 , and R^3 are all C_{1-4} alkoxy;

R^4 and R^6 are independently selected from hydrogen, hydroxy, C_{1-3} alkoxy, and

20 C_{1-3} alkyl;

R^5 is methoxy;

A is $-CO-$, $-C(O)O-$ or $-CONH-$;

a is 1, 2 or 3;

B is $-CO-$, $-NHCO-$, $-CONH-$, $-C(O)O-$, $-NH-$, $-NHC(O)O-$, $NHCONH-$ or a single direct

25 bond;

b is 0, 1 or 2;

D is carboxy, sulpho, phosphoryloxy, hydroxy, amino, N - C_{1-4} alkylamino, N,N -di(C_{1-4}

alkyl)amino or of the formula $-Y^1(CH_2)_cR^{11}$ (wherein Y^1 is $-NHC(O)-$ or $-C(O)NH-$; c is 1 or 2; R^{11} is a 5-6-membered saturated heterocyclic group (linked via nitrogen)

30 containing 1 or 2 ring heteroatoms, selected independently from O and N, which heterocyclic group may bear 1 or 2 substituents selected from:

- 11 -

C₁₋₄ alkyl, C₂₋₄alkanoyl, carbamoyl, cyanoC₁₋₃alkyl, hydroxyC₁₋₃alkyl, carboxyC₁₋₃alkyl and aminoC₁₋₃alkyl);

R⁷ is hydrogen;

or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.

5

Another preferred class of compound is of the formula (I) wherein:

R¹, R², and R³ are all methoxy;

R⁴ and R⁶ are independently selected from hydrogen, hydroxy, methoxy and methyl;

R⁵ is methoxy;

10 A is -CO-, -C(O)O- or -CONH-;

a is 2 or 3;

B is -CO-, -NHCO-, -CONH or a single direct bond;

b is 0 or 1;

D is carboxy, phosphoryloxy, hydroxy, amino, N-C₁₋₄ alkylamino, N,N-di(C₁₋₄ alkyl)amino or


15 of the formula -Y¹(CH₂)_cR¹¹ (wherein Y¹ is -NHC(O)- or -C(O)NH-; c is 1 or 2; R¹¹ is piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring nitrogen atom and each ring is optionally substituted by 1 or 2 substituents selected from:

C₁₋₄alkyl, C₂₋₄alkanoyl, carbamoyl, cyanoC₁₋₃alkyl, hydroxyC₁₋₃alkyl, carboxyC₁₋₃alkyl and aminoC₁₋₃alkyl);

20 R⁷ is hydrogen;

or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.

Another preferred class of compounds is that of the formula (II):



25

wherein a, b, A, B and D are as hereinabove defined;

- 12 -

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

Another preferred class of compounds is that of the formula (II) wherein:

A is -CO-, -C(O)O- or -CONH-;

5 a is 2 or 3;

B is -CO-, -NHCO-, -CONH or a single direct bond;

b is 0 or 1;

D is carboxy, phosphoryloxy, hydroxy, amino, N-C₁₋₄ alkylamino, N,N-di(C₁₋₄ alkyl)amino or
of the formula -Y^I(CH₂)_cR^{II} (wherein Y^I is -NHC(O)- or -C(O)NH-; c is 1 or 2; R^{II} is

10 piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring nitrogen atom
and each ring is optionally substituted by 1 or 2 substituents selected from:

C₁₋₄alkyl, C₂₋₄alkanoyl, carbamoyl, cyanoC₁₋₃alkyl, hydroxyC₁₋₃alkyl, carboxyC₁₋₃alkyl
and aminoC₁₋₃alkyl);

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

15

Another preferred class of compounds is that of the formula (II) wherein:

A is -CO-, -C(O)O- or -CONH-;

a is 2 or 3;

B is -CO-, -NHCO-, -CONH or a single direct bond;

20 b is 0 or 1;

D is phosphoryloxy, carboxy, amino or imidazolyl;

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

Another preferred class of compounds is that of the formula (II) wherein:

25 A is -CO-, -C(O)O- or -CONH-;

a is 2 or 3;

B is -CO-, -NHCO- or a single direct bond;


b is 0 or 1;

D is phosphoryloxy amino or imidazolyl;

30 or a pharmaceutically acceptable salt, solvate or prodrug thereof.

- 13 -

A further preferred class of compounds of the invention is that of a compound of formula (III)::



(III)

wherein:

R¹, R² and R³ are each independently hydroxy, phosphoryloxy (-OPO₃H₂), C₁₋₄alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R¹, R² and R³ are C₁₋₄alkoxy;

A is -CO-, -C(O)O-, -CON(R⁸)-, -SO₂- or -SO₂N(R⁸)- (wherein R⁸ is hydrogen, C₁₋₄alkyl, C₁₋₃alkoxyC₂₋₃alkyl, aminoC₂₋₃alkyl or hydroxyC₂₋₃alkyl);

a is an integer from 1 to 4 inclusive;

R^a and R^b are independently selected from hydrogen, hydroxy and amino;

B is -O-, -CO-, -N(R⁹)CO-, -CON(R⁹)-, -C(O)O-, -N(R⁹)-, -N(R⁹)C(O)O-,

-N(R⁹)CON(R¹⁰)-, -N(R⁹)SO₂-, -SO₂N(R⁹)- or a direct single bond (wherein R⁹ and R¹⁰ are independently selected from hydrogen, C₁₋₄alkyl, C₁₋₃alkoxyC₂₋₃alkyl, aminoC₂₋₃alkyl and hydroxyC₂₋₃alkyl);

b is 0 or an integer from 1 to 4 inclusive;

D is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O and N, which heterocyclic group may bear 1 or 2 substituents selected from:

oxo, hydroxy, halogeno, C₁₋₄alkyl, C₂₋₄alkanoyl, carbamoyl, N-(C₁₋₄alkyl)carbamoyl,

N,N-di-(C₁₋₄alkyl)carbamoyl, hydroxyC₁₋₄alkyl, C₁₋₄alkoxy, cyanoC₁₋₃alkyl,

carbamoylC₁₋₃alkyl, carboxyC₁₋₄alkyl, aminoC₁₋₄alkyl, N-C₁₋₄alkylaminoC₁₋₄alkyl, di-

N,N-(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkylsulphonylC₁₋₄alkyl and

R¹⁴ (wherein R¹⁴ is a 5-6-membered saturated heterocyclic group (linked via carbon or

- 14 -

nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O and N,
which heterocyclic group is optionally substituted by 1 or 2 substituents selected from:

oxo, hydroxy, halogeno, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkoxy,
C₁₋₄alkoxyC₁₋₄alkyl and C₁₋₄alkylsulphonylC₁₋₄alkyl);

5 R⁵ is C₁₋₄alkoxy;

R⁴ and R⁶ are each independently selected from:

hydrogen, halogeno, nitro, amino, N-C₁₋₄alkylamino, N,N-di-(C₁₋₄alkyl)amino, hydroxy,
C₁₋₄alkoxy and C₁₋₄alkyl;

R⁷ is hydrogen, C₁₋₄alkyl, C₁₋₃alkoxyC₁₋₃alkyl, aminoC₁₋₃alkyl or hydroxyC₁₋₃alkyl;

10 or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

Another further preferred class of compound is of the formula (III) wherein:

R¹, R², and R³ are all C₁₋₄alkoxy;

R⁴ and R⁶ are independently selected from hydrogen, hydroxy, C₁₋₃alkoxy, and C₁₋₃alkyl;

15 R⁵ is methoxy;

A is -CO-, -C(O)O- or -CONH-;

a is 1, 2 or 3;

B is -CO-, -NHCO-, -CONH-, -C(O)O-, -NH-, -NHC(O)O-, NHCONH- or a single direct
bond;

20 b is 0, 1 or 2;

D is piperazinyl or morpholinyl or piperidinyl, each ring being optionally substituted by 1 or 2
substituents selected from C₁₋₄alkyl, C₂₋₄alkanoyl, carbamoyl, cyanoC₁₋₃alkyl,
hydroxyC₁₋₃alkyl, carboxyC₁₋₃alkyl and aminoC₁₋₃alkyl;

R⁷ is hydrogen;

25 or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.

Another further preferred class of compound is of the formula (III) wherein:

R¹, R², and R³ are all methoxy;

R⁴ and R⁶ are independently selected from hydrogen, hydroxy, methoxy and methyl;

30 R⁵ is methoxy;

A is -CO-, -C(O)O- or -CONH-;

a is 2 or 3;

- 15 -

B is -CO-, -NHCO-, -CONH or a single direct bond;


b is 0 or 1;

D is piperazino or morpholino, each ring being optionally substituted by 1 or 2 substituents selected from methyl, ethyl, acetyl, propionyl, carbamoyl and 2-hydroxyethyl;

5 R⁷ is hydrogen;

or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.

In another aspect the invention relates to a compound of the formula (IV):



10 wherein a, b, A, B and D are as hereinabove defined for formula (III);

or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.

Another preferred class of compounds is that of the formula (IV) wherein:

A is -CO-, -C(O)O- or -CONH-;

15 a is 2 or 3;

B is -CO-, -NHCO-, -CONH or a single direct bond;

b is 0 or 1;

D is piperazino or morpholino, each ring being optionally substituted by 1 or 2 substituents selected from methyl, ethyl, acetyl, propionyl, carbamoyl and 2-hydroxyethyl;

20 or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

Another preferred class of compounds is that of the formula (IV) wherein:

A is -CO-, -C(O)O- or -CONH-;

a is 2 or 3;

25 B is -CO-, -NHCO-, -CONH or a single direct bond;

b is 0 or 1;

D is morpholino, 4-methylpiperazin-1-yl or 4-acetylpiperazin-1-yl;

or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

- 16 -

Another preferred class of compounds is that of the formula (IV) wherein:

A is -CO-, -C(O)O- or -CONH-;

a is 2 or 3;

5 B is -CO- or a single direct bond;

b is 0;

D is morpholino, 4-methylpiperazin-1-yl or 4-acetylpiperazin-1-yl;
or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

10 Particular compounds of the present invention include:

N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-2-[2-aminoacetylamino]acetamide;

4-oxo-4-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]amino]butyl disodium phosphate;

15 N-{N-[2-(imidazol-1-yl)ethyl]carbamoyl}-5(S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine; and

2-{N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamoyloxy}ethyl disodium phosphate;

and pharmaceutically-acceptable salts, solvates or pro-drugs thereof.

20

Further particular compounds of the present invention include:

2-morpholinoethyl N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamate;

3-(1-methylpiperazin-4-yl)propyl N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl] carbamate;

25 N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-2-[2-aminoacetylamino]acetamide;

2-(1-acetylpiperazin-4-yl)ethyl-N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl] carbamate;

30 N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-4-(1-methylpiperazin-4-yl)-4-oxobutan-1-amide;

- 17 -

- 4-oxo-4-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]amino]butyl disodium phosphate;
- N-{N-[2-(imidazol-1-yl)ethyl]carbamoyl}-5(S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine;
- 5 3-(1-acetylpiperazin-4-yl) propyl-N-[(5S)-3,9,10,11-tetramethoxy-6-7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamate;
- N-1-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamoyloxy]ethyl disodiumphosphate;
- 4-morpholino-4-oxobutyl-N-[(5S)-3,9,10, 11-tetramethoxy-6,7-dihydro-5H-dibenzo
- 10 [a-c]cyclohepten-5-yl]carbamate; and
- 4-(1-methylpiperazin-4-yl)-4-oxobutyl-N-[(5S)-3,9,10, 11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cylcohepten-5-yl]carbamate;
- and pharmaceutically-acceptable salts, , solvates or pro-drugs thereof.

15 Synthesis of Compounds of the Formula (I)

Compounds of Formula (I) may be prepared by a number of processes as generally described hereinbelow and more specifically in the Examples hereinafter. Processes for the preparation of novel compounds of formula (I), are provided as a further feature of the invention and are as described hereinafter. Necessary starting materials may be obtained by

20 standard procedures of organic chemistry. The preparation of such starting materials is described within the accompanying non-limiting Examples. Alternatively necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.

Thus according to another aspect of the invention, a compound of the Formula (I) may

25 be formed by deprotecting a compound of the formula (I) wherein at least 1 functional group is protected. For example, amino, hydroxy, carboxy or phosphoryloxy groups may be protected during the reaction sequence used to prepare a compound of the formula (I).

Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in

30 question, and may be introduced by conventional methods.

Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting

- 18 -

group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

A suitable protecting group for a hydroxy group is, for example, an arylmethyl group (especially benzyl), a triC₁₋₄alkylsilyl group (especially trimethylsilyl or tert-butyldimethylsilyl),
5 an aryldi-C₁₋₄alkylsilyl group (especially dimethylphenylsilyl), a diarylC₁₋₄alkylsilyl group (especially tert-butyldiphenylsilyl), a C₁₋₄alkyl group (especially methyl), a C₂₋₄alkenyl group (especially allyl), a C₁₋₄alkoxymethyl group (especially methoxymethyl) or a tetrahydropyranyl group (especially tetrahydro-2H-pyran-2-yl). The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for an
10 example, arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal. Alternatively a trialkylsilyl or an aryldialkylsilyl group such as tert-butyldimethylsilyl or a dimethylphenylsilyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric, phosphoric or trifluoroacetic acid, or with an alkali metal or ammonium fluoride such as
15 sodium fluoride or, preferably tetrabutylammonium fluoride. Alternatively an alkyl group may be removed, for example, by treatment with an alkali metal C₁₋₄alkylsulphide such as sodium thioethoxide or, for example, by treatment with an alkali metal diarylphosphide such as lithium diphenylphosphide or, for example, by treatment with a boron or aluminium trihalide such as boron tribromide. Alternatively a C₁₋₄alkoxymethyl group or
20 tetrahydropyranyl group may be removed, for example, by treatment with a suitable acid such as hydrochloric or trifluoroacetic acid.

Alternatively a suitable protecting group for a hydroxy group is, for example, an acyl group, for example a C₂₋₄alkanoyl group (especially acetyl) or an aroyl group (especially benzoyl). The deprotection conditions for the above protecting groups will necessarily vary
25 with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.

A suitable protecting group for an amino, imino or alkylamino group is, for example, an acyl group, for example a C₂₋₄alkanoyl group (especially acetyl), a C₁₋₄alkoxycarbonyl group (especially methoxycarbonyl), ethoxycarbonyl or tert-butoxycarbonyl), an
30 arylmethoxycarbonyl group (especially benzyloxycarbonyl) or an aroyl group (especially benzoyl). The deprotection conditions for the above protecting groups necessarily vary with

- 19 -

the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl, alkoxy carbonyl or aroyl group may be removed for example, by hydrolysis with a suitable base such as alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment
 5 with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid, and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-charcoal.


A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a C₁₋₄alkyl group (especially methyl or ethyl) which may be removed, for
 10 example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide; or for example, a tert-butyl group which may be removed, for example, by treatment with a suitable acid such as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid.

The reader is referred to Advanced Organic Chemistry, 4th Edition, by J. March,
 15 published by John Wiley & Sons 1992, for general guidance on reaction conditions and reagents and to Protective Groups in Organic Synthesis, 2nd Edition, by T. Green et al., also published by John Wiley & Son, for general guidance on protecting groups.

In the following process description the symbols R¹ - R⁷, A, B, D, R^a R^b, a and b are to be understood to represent those groups described above in relation to formulae (I) and (II)
 20 unless otherwise stated.


A compound of the formula (I), or a compound of the formula (I) wherein at least 1 functional group is protected, may be prepared using one of the following processes:

- a) reacting a compound of the formula (X)



25

with a compound of the formula (XI):



- 20 -

wherein L^1 is a leaving group; or

b) converting one compound of the formula (I) into another compound of the formula (I); or

c) when a phosphoryloxy group is desired, reacting the corresponding hydroxy
5 compound with a phosphoramidite;

wherein any functional groups are optionally protected.

and thereafter if necessary:

i) converting a compound of formula (I) into another compound of formula (I);

ii) removing any protecting groups;

10 iii) forming a pharmaceutically acceptable salt, solvate or pro-drug thereof.

The reaction between a compound of the formula (X) and a compound of the formula $L^1 - A - [CH(R^a)]_a - B - [CH(R^b)]_b - D$ is conveniently performed under standard acylation or sulphonylation conditions. L^1 is usually halogeno, for example chloro or bromo, hydroxy,
15 mesyloxy, tosyloxy or an 'activated' hydroxy group. The precise conditions depending largely upon the nature of A.

For example, when -A- is -CO-, L^1 may be hydroxy and the reaction carried out in the presence of coupling agent such as dicyclohexylcarbodiimide or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide. Optionally, a base may be used, for example an organic base such as
20 triethylamine. Suitable solvents are usually aprotic solvents, for example dimethylformamide, or chlorinated solvents, for example trichloromethane or dichloromethane. The temperature is usually in the range of about -30°C to about 60°C, conveniently at or near ambient temperature.

When -A- is -C(O)O-, L^1 is usually an "activated" hydroxy group. That is a group
25 which acts as a leaving group in the same way as hydroxy, but is more labile. It can be formed in situ. An example of an activated hydroxy group is 4-nitrophenoxy, which can be formed by reacting a hydroxy group ($HO - [CH(R^a)]_a - B - [CH(R^b)]_b - D$) with 4-nitrophenylchloroformate. This reaction is usually carried out in an organic solvent such as dichloromethane, acetonitrile or tetrahydrofuran, in a temperature range of about -20°C to the
30 reflux temperature of the solvent. In addition, organic base such as triethylamine or N-methylmorpholine is normally present. Alternatively, a compound of the formula (X) can be reacted with 4-nitrophenylchloroformate and the resulting intermediate reacted with

- 21 -

HO-[CH(R^a)]_a-B-[CH(R^b)]_b-D under similar conditions to those described above for the reaction of a compound of the formula (X) with a compound of the formula L²-[CH(R^a)]_a-B-[CH(R^b)]_b-D wherein L² is 4-nitrophenoxy.

When -A- is -CON(R⁸)-, L¹ is preferably halogeno, particularly chloro. Alternatively
5 when -A- is -CONH-, a compound of the formula (X) can be reacted with an isocyanate of the formula C≡N-[CH(R^a)]_a-B-[CH(R^b)]_b-D. These reactions are conveniently carried out in the presence of a base, particularly an organic base, such as triethylamine, pyridine or N-methylmorpholine, in a solvent such as an ether solvent, for example tetrahydrofuran, or in a chlorinated solvent, for example dichloromethane, at a temperature in the range from about -
10 20°C to the reflux temperature of the solvent. Alternatively, a compound of the formula (X) can be reacted with 4-nitrophenylchloroformate and the resulting intermediate reacted with R¹⁷-NH₂ under similar conditions to those described above for the reaction of a compound of the formula (X) with a compound of the formula L²-[CH(R^a)]_a-B-[CH(R^b)]_b-D wherein L² is 4-nitrophenoxy.

15 When -A- is of the formula -SO₂- or -SO₂N(R⁸)-, L¹ is preferably halogeno, for example chloro. The reaction is conveniently carried out in the presence of a base such as dimethylaniline, in a chlorinated solvent such as trichloromethane and at a temperature in the range of -20°C to about 60°C, more preferably in pyridine, at a temperature in the range from -20°C to about 60°C.

20 A compound of formula (I) may be prepared from another compound of formula (I) by chemical modification. Examples of chemical modifications include standard alkylation, arylation, heteroarylation, acylation, sulphonylation, phosphorylation, aromatic halogenation and coupling reactions. These reactions may be used to add new substituents or to modify existing substituents. Alternatively, existing substituents in compounds of formula (I) may
25 be modified by, for example, oxidation, reduction, elimination, hydrolysis or other cleavage reactions to yield other compounds of formula (I).

Thus for example a compound of formula (I) containing an amino group may be acylated on the amino group by treatment with, for example, an acyl halide or anhydride in the presence of a base, for example a tertiary amine base such as triethylamine, in for example, a
30 solvent such as a hydrocarbon solvent e.g. dichloromethane at a temperature in the range for example -30°C to 120°C, conveniently at or near ambient temperature.

- 22 -

In another general example of an interconversion process, an amino group in a compound of formula (I) may be sulphonylated by treatment with, for example, an alkyl or aryl sulphonyl chloride or an alkyl or aryl sulphonic anhydride in the presence of a base, for example a tertiary amine base such as triethylamine, in for example a solvent such as a hydrocarbon solvent e.g. dichloromethane, at a temperature in the range for example -30°C to 120°C, conveniently at or near ambient temperature.

In a further general example, a compound of formula (I) containing a hydroxy group can be converted into the corresponding dihydrogenphosphate ester by treatment with for example di-tert-butyl diisopropylphosphoramidite or di-tert-butyl diethylphosphoramidite in the presence of a suitable catalyst, for example tetrazole. A solvent such as an ether solvent, for example tetrahydrofuran can be used. The reaction is usually carried out at a temperature in the range -40°C to 40°C, conveniently at or near ambient temperature, followed by treatment with an oxidising agent for example 3-chloroperoxy benzoic acid at a temperature in the range -78°C to 40°C preferably -40°C to 10°C. The resulting intermediate phosphate triester is treated with an acid, for example trifluoroacetic acid, in a solvent such as a chlorinated solvent e.g. dichloromethane at a temperature in the range -30°C to 40°C, conveniently at or near 0°C, to give the compound of formula (I) containing a dihydrogenphosphate ester.

In a further general example a compound of formula (I) containing an amide can be hydrolysed by treatment with for example an acid such as hydrochloric acid in a solvent such as an alcohol, for example methanol at an elevated temperature conveniently at the reflux temperature.

In another general example an alkoxy group may be converted to the corresponding alcohol (OH) by reaction with boron tribromide in a solvent such as a chlorinated solvent e.g. dichloromethane at a low temperature e.g. around -78°C.

In a further general example a compound of formula (I) may be alkylated by reaction with a suitable alkylating agent such as an alkyl halide, an alkyl toluenesulphonate, an alkyl methanesulphonate or an alkyl triflate. The alkylation reaction can be carried out in the presence of a base, for example an inorganic base such as a carbonate e.g. caesium or potassium carbonate, a hydride such as sodium hydride or an alkoxide such as potassium t-butoxide, in a suitable solvent such as an aprotic solvent e.g. dimethylformamide or an ether solvent such as tetrahydrofuran, at a temperature of around -10°C to 80°C.

- 23 -


In a further example, an unsubstituted ring nitrogen in a saturated heterocyclic ring may be acylated using similar reaction conditions to those described above for the acylation of an amino group.

Synthesis of Intermediates

5 A compound of the formula (X) may be known or prepared according to processes described in International Patent Application No. PCT/GB98/01977.

A compound of the formula (XI) may be known or prepared by methods known in the art. For example, when A is of the formula -C(O)O- and L¹ is 4-nitrophenyloxy, the compound of the formula (XI) may be formed by reacting a compound of the formula:

10



with 4-nitrophenyl chloroformate, in the presence of a base, preferably an organic base such as triethylamine, in an inert organic solvent such as dichloromethane. The reaction is usually
15 carried out in a temperature range of -30°C to 60°C, most commonly at around ambient temperature.

Acid addition salts of the compounds of formula (I) are prepared in a conventional manner by treating a solution or suspension of the free base of a compound of formula (I) with about one equivalent of a pharmaceutically acceptable acid. Salts of compounds of formula
20 (I) derived from inorganic or organic bases are prepared in a conventional manner by treating a solution or suspension of the free acid of a compound of formula (I) with about one equivalent of a pharmaceutically acceptable organic or inorganic base. Alternatively both acid addition salts and salts derived from bases may be prepared by treatment of the parent compound with the appropriate ion-exchange resin in a standard fashion. Conventional
25 concentration and recrystallisation techniques are employed in isolating the salts.

Compounds according to the invention are able to destroy vasculature that has been newly formed such as tumour vasculature while leaving unaffected normal, mature vasculature. The identification of compounds which selectively, and preferably potently, damage newly-formed vasculature is desirable and is the subject of the present invention. The
30 ability of the compounds to act in this way may be assessed, for example, using one or more of the procedures set out below:

- 24 -

(a) Activity against tumour vasculature measured by radioactive tracer

This assay demonstrates the ability of compounds to damage selectively tumour vasculature.

Subcutaneous CaNT tumours were initiated by injecting 0.05ml of a crude tumour cell suspension, approximately 10^6 cells, under the skin overlying the rear dorsum of 12-16 week-old mice. The animals were selected for treatment after approximately 3-4 weeks, when their tumours reached a geometric mean diameter of 5.5-6.5 mm. Compounds were dissolved in sterile saline and injected intraperitoneally in a volume of 0.1 ml per 10g body weight. Tumour perfusion was measured 6 hours after intraperitoneal administration in tumour, kidney, liver, skin, muscle, gut and brain by the $^{86}\text{RbCl}$ extraction technique (Sapirstein, Amer. Jnl. Physiol., 1958, 193, 161-168). Tissue radioactivity measured 1 minute after an intravenous injection of $^{86}\text{RbCl}$ was used to calculate relative blood flow as a proportion of cardiac output (Hill and Denekamp, Brit. Jnl. Radiol., 1982, 55, 905-913). Five animals were used in control and treated groups. Results were expressed as a percentage of the blood flow in the corresponding tissues in vehicle treated animals.

(b) Activity against tumour vasculature measured by fluorescent dye

This assay demonstrates the ability of compounds to damage tumour vasculature.

Tumour functional vascular volume in CaNT tumour-bearing mice was measured using the fluorescent dye Hoechst 33342 according to the method of Smith et al (Brit. Jnl. Cancer 1988, 57, 247-253). Five animals were used in control and treated groups. The fluorescent dye was dissolved in saline at 6.25mg/ml and injected intravenously at 10mg/kg 24 hours after intraperitoneal drug treatment. One minute later, animals were killed and tumours excised and frozen; 10 μm sections were cut at 3 different levels and observed under UV illumination using an Olympus microscope equipped with epifluorescence. Blood vessels were identified by their fluorescent outlines and vascular volume was quantified using a point scoring system based on that described by Chalkley, (Jnl. Natl. Cancer Inst., 1943, 4, 47-53). All estimates were based on counting a minimum of 100 fields from sections cut at the 3 different levels.

The ability of the compounds to bind to preparations of mammalian tubulin can be evaluated by a number of methods available in the literature, for example by following temperature initiated tubulin polymerisation by turbidity in the absence and presence of the compound (for example O.Boye *et al* Med. Chem. Res., 1991, 1, 142-150).

- 25 -

The activity of *N*-[3-amino-9,10,11-trimethoxy-6,7-dihydro-5*H*-dibenzo[*a,c*]cyclohepten-5-yl]acetamide, (V. Fernholz Justus Liebigs Ann., 1950, 568, 63-72), against tumour vasculature was measured by the fluorescent dye method described above. This compound decreased perfused vascular volume by 88% relative to control when dosed at 50mg/kg intraperitoneally. The IC₅₀ of this compound in a tubulin polymerisation assay was 58 micromolar (O.Boye *et al* Med. Chem. Res., 1991, 1, 142-150).

(c) HUVEC detachment assay

This assay examined the effects of compounds on the adherence of HUVECs to tissue culture plasticware.

HUVECs were plated in 0.2% gelatin-coated 12 well tissue culture plates at a concentration of 3×10^4 cells per well in 1ml TCS medium. After 24 hours, when the cells were at ~30% confluency, the cells were dosed with compound for 40 minutes at 37°C, 5% CO₂. After this incubation the medium containing drug was pipetted off, and the cells were then gently washed in 2mls of HBSS (Hanks' Balanced Salt Solution purchased from Life Technologies Ltd, Paisley UK; Catalogue # 24020-083) to remove any detached cells. The washing solution was then removed, and the adherent cells remaining were trypsinised using 300µl of 1x Trypsin-EDTA solution (Life Technologies Ltd, Paisley, UK; Catalogue # 43500-019) at ambient temperature for 2 minutes. The trypsinised cells were then made up to 1ml with TCS Biologicals medium, then centrifuged at 2000rpm for 2 minutes. The cell pellet was then resuspended in a volume of 50µl of TCS Biologicals medium. Total cell counts were obtained by counting the cells on a haemocytometer. The amount of cell detachment was calculated by comparing the number of cells remaining attached following treatment with the number in undosed control wells.

(d) Hras5 necrosis model

NIH 3T3 fibroblasts transfected with Harvey ras, clone 5, (Hras5 cells) were kept in continual passage in Dulbecco's modified Eagles medium (DMEM) containing 10% foetal bovine serum (FBS) and 1% glutamine, at 37°C in a humidified incubator gassed with 7.5% carbon dioxide and 92.5% oxygen. Cells were implanted subcutaneously into the left flank of male nude mice (8-10weeks of age) at an inoculum of 2×10^5 cells/mouse. Tumours were measured using calipers and randomised into groups of 2-4 mice between days 9-14 after implant. Mice were dosed with compounds, either intravenously or intraperitoneally, once on

- 26 -

day of randomisation and culled 24 hours after dosing. Compounds were dissolved in 20% hydroxypropyl beta cyclodextrin in physiological saline at pH 7 and dosed in a volume of 0.1ml per 10g body weight. Tumours were excised, weighed and placed in buffered formalin. Area of necrosis in individual tumours was assessed from a haematoxylin/eosin stained-slide
5 by a pathologist and scored from 0, meaning no significant change, to 10, meaning 91-100% necrosis. The activity of examples 5 and 7 (described hereinafter) against tumour vasculature was measured by the fluorescent dye method described hereinabove. Example 1 scored 6.0 at 100m/kg and example 4 scored 3.2 at 50m/kg.

According to a further aspect of the invention there is provided a pharmaceutical
10 composition which comprises a compound of the formula (I) as defined hereinbefore or a pharmaceutically acceptable salt, solvate or pro-drug thereof, in association with a pharmaceutically acceptable excipient or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for nasal administration or administration by inhalation, for example as a
15 powder or solution, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical administration for example as an ointment or cream or for rectal administration for example as a suppository. In general the above compositions may be prepared in a conventional manner using conventional excipients.

20 The compositions of the present invention are advantageously presented in unit dosage form. The compound will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000mg per square metre body area of the animal, i.e. approximately 0.1-100mg/kg. A unit dose in the range, for example, 1-100mg/kg, preferably 1-50mg/kg is envisaged and this normally provides a therapeutically-effective dose. A unit
25 dose form such as a tablet or capsule will usually contain, for example 1-250mg of active ingredient.

As stated above the size of the dose required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Preferably a daily
30 dose in the range of 1-50mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity

- 27 -

of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

According to a further aspect of the present invention there is provided a compound of the formula (I) or a pharmaceutically acceptable salt, solvate or pro-drug thereof as defined
5 hereinbefore for use in a method of treatment of the human or animal body by therapy.

A further feature of the present invention is a compound of formula (I), or a pharmaceutically acceptable salt, solvate or pro-drug thereof, for use as a medicament, conveniently a compound of formula (I), or a pharmaceutically acceptable salt, solvate or pro-drug thereof, for use as a medicament for producing a vascular damaging effect in a
10 warm-blooded animal such as a human being.

Thus according to a further aspect of the invention there is provided the use of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal such as a human being.

15 According to a further feature of the invention there is provided a method for producing a vascular damaging effect in a warm-blooded animal, such as a human being, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or pro-drug thereof as defined hereinbefore.

20 According to a further aspect of the present invention there is provided a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition, when dosed in divided doses (also known as split doses) produces a greater anti-tumour effect than when a single dose is given.

Anti-tumour effects of a method of treatment of the present invention include but are
25 not limited to, inhibition of tumour growth, tumour growth delay, regression of tumour, shrinkage of tumour, increased time to re-growth of tumour on cessation of treatment, slowing of disease progression. It is expected that when a method of treatment of the present invention is administered to a warm-blooded animal such as a human, in need of treatment for cancer involving a solid tumour, said method of treatment will produce an effect, as measured
30 by, for example, one or more of: the extent of the anti-tumour effect, the response rate, the time to disease progression and the survival rate.

- 28 -

According to a further aspect of the present invention there is provided a method for the production of a vascular damaging effect in a warm-blooded animal such as a human, which comprises administering to said animal in divided doses an effective amount of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition.

According to a further aspect of the present invention there is provided a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal in divided doses an effective amount of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition.

According to a further aspect of the present invention there is provided a medicament comprising two or more fractions of doses of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition, which together add up to a total daily dose, for administration in divided doses for use in a method of treatment of a human or animal body by therapy.

According to a further aspect of the present invention there is provided a kit comprising two or more fractions of doses of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof, preferably in the form of a pharmaceutical composition, which together add up to a total daily dose, for administration in divided doses.

According to a further aspect of the present invention there is provided a kit comprising:

- a) two or more fractions of doses of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof, which together add up to a total daily dose, in unit dosage forms for administration in divided doses; and
- b) container means for containing said dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- a) two or more fractions of doses of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof, which together add up to a total daily dose, together with a pharmaceutically acceptable excipient or carrier, in unit dosage forms; and
- b) container means for containing said dosage forms.

- 29 -

According to a further aspect of the present invention there is provided the use of compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for administration in divided doses for use in the production of a vascular damaging effect in a warm-blooded animal such as a human.

5 According to a further aspect of the present invention there is provided the use of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for administration in divided doses for use in the production of an anti-cancer effect in a warm-blooded animal such as a human.

10 According to a further aspect of the present invention there is provided the use of a compound of formula (I) or pharmaceutically-acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for administration in divided doses for use in the production of an anti-tumour effect in a warm-blooded animal such as a human.

Divided doses, also called split doses, means that the total dose to be administered to a warm-blooded animal, such as a human, in any one day period (for example one 24 hour
15 period from midnight to midnight) is divided up into two or more fractions of the total dose and these fractions are administered with a time period between each fraction of about greater than 0 hours to about 10 hours, preferably about 1 hour to about 6 hours, more preferably about 2 hours to about 4 hours. The fractions of total dose may be about equal or unequal.

Preferably the total dose is divided into two parts which may be about equal or unequal.
20 The time intervals between doses may be for example selected from:
about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 5.5 hours and about 6 hours.

The time intervals between doses may be any number (including non-integers) of minutes between greater than 0 minutes and 600 minutes, preferably between 45 and 375
25 minutes inclusive. If more than two doses are administered the time intervals between each dose may be about equal or unequal.

Preferably two doses are given with a time interval in between them of greater than or equal to 1 hour and less than 6 hours.

More preferably two doses are given with a time interval in between them of greater
30 than or equal to two hours and less than 5 hours.

Yet more preferably two doses are given with a time interval in between them of greater than or equal to two hours and less than or equal to 4 hours.

- 30 -

Particularly the total dose is divided into two parts which may be about equal or unequal with a time interval between doses of greater than or equal to about two hours and less than or equal to about 4 hours.

More particularly the total dose is divided into two parts which may be about equal with
5 a time interval between doses of greater than or equal to about two hours and less than or equal to about 4 hours.

For the avoidance of doubt the term 'about' in the description of time periods means the time given plus or minus 15 minutes, thus for example about 1 hour means 45 to 75 minutes, about 1.5 hours means 75 to 105 minutes. Elsewhere the term 'about' has its usual dictionary
10 meaning.

The antiangiogenic treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In the
15 field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment in addition to the antiangiogenic treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy. Such chemotherapy may include the following categories of therapeutic agent:

- 20 (i) other antiangiogenic agents that work by different mechanisms from those defined hereinbefore (for example linomide, inhibitors of integrin $\alpha v \beta 3$ function, angiostatin, endostatin, razoxin, thalidomide) and including vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (RTKIs) (for example those described in International Patent Applications Publication Nos. WO 97/22596, WO 97/30035, WO 97/32856 and WO
25 98/13354 the entire disclosure of which documents is incorporated herein by reference);
- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene), progestogens (for example megestrol acetate), aromatase inhibitors (for example anastrozole, letrozole, vorazole, exemestane), antiprogestogens, antiandrogens (for example flutamide, nilutamide, bicalutamide, cyproterone acetate), LHRH agonists and
30 antagonists (for example goserelin acetate, luprolide), inhibitors of testosterone 5 α -dihydroreductase (for example finasteride), anti-invasion agents (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator

- 31 -

receptor function) and inhibitors of growth factor function, (such growth factors include for example epidermal growth factor (EGF), platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors);

- 5 (iii) biological response modifiers (for example interferon);
(iv) antibodies (for example edrecolomab); and
(v) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as antimetabolites (for example antifolates like methotrexate, fluoropyrimidines like 5-fluorouracil, purine and adenosine analogues, cytosine arabinoside);
10 antitumour antibiotics (for example anthracyclines like doxorubicin, daunomycin, epirubicin and idarubicin, mitomycin-C, dactinomycin, mithramycin); platinum derivatives (for example cisplatin, carboplatin); alkylating agents (for example nitrogen mustard, melphalan, chlorambucil, busulphan, cyclophosphamide, ifosfamide, nitrosoureas, thiotepa); antimitotic agents (for example vinca alkaloids like vincristine and taxoids like taxol, taxotere); enzymes
15 (for example asparaginase); thymidylate synthase inhibitors (for example raltitrexed); topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan, irinotecan).

As stated above the compounds defined in the present invention are of interest for their vascular damaging effects. Such compounds of the invention are expected to be useful
20 in the prophylaxis and treatment of a wide range of disease states where inappropriate angiogenesis occurs including cancer, diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation. In particular such compounds of the
25 invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, breast, prostate, lungs and skin.

In addition to their use in therapeutic medicine, the compounds of formula (I) and their pharmaceutically acceptable salts, solvates or pro-drugs are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test
30 systems for the evaluation of the effects of vascular damaging agents in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

- 32 -


It is to be understood that where the term "ether" is used anywhere in this specification it refers to diethyl ether.

The invention will now be illustrated in the following non-limiting Examples in which, unless otherwise stated:

- 5 (i) evaporations were carried out by rotary evaporation in vacuo and work-up procedures were carried out after removal of residual solids such as drying agents by filtration;
- (ii) operations were carried out at ambient temperature, that is in the range 18-25°C and under an atmosphere of an inert gas such as argon or nitrogen;
- (iii) yields are given for illustration only and are not necessarily the maximum
- 10 attainable;
- (iv) the structures of the end-products of the formula (I) were confirmed by nuclear (generally proton) magnetic resonance (NMR) and mass spectral techniques; proton magnetic resonance chemical shift values were measured on the delta scale and peak multiplicities are shown as follows: s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; q, quartet, quin,
- 15 quintet;
- (v) intermediates were not generally fully characterised and purity was assessed by thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), infra-red (IR) or NMR analysis;

20 Abbreviations

4-Dimethylaminopyridine	DMAP
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride	EDCI
Dimethyl sulfoxide	DMSO
25 Trifluoroacetic acid	TFA

Example 1**N-[(5S)-3,9,10,11-Tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-2-[2-aminoacetylamino]acetamide**

5

A solution of N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-2-[2-(butoxycarbonylamino)acetylamino]acetamide (0.9 g ; 0.64 mmol) in dichloromethane (6 ml) was treated with TFA (6 ml) at ambient temperature for 0.5 hour. After evaporation to dryness, the residue was neutralised to pH 6.5 with solid sodium hydrogen carbonate and
 10 purified on reverse phase silica eluting with a gradient of 30-40 % methanol / ammonium carbonate buffer (2 g / l, pH 7). The appropriate fractions were evaporated to dryness and triturated in ether to give the title compound.


Yield : 65 %

¹H NMR (DMSO-d₆) : 1.88-2.21 (m, 3H) ; 2.58 partially obscured by DMSO peak (m, 1H) ;
 15 3.10 (s, 2H) ; 3.46 (s, 3H) ; 3.79 (s, 3H) ; 3.82 (s, 3H) ; 3.83 (s, 3H) ; 3.84 (s, 3H) ; 4.47-4.58 (m, 1H) ; 6.77 (s, 1H) ; 6.87 (dd, 1H) ; 6.91 (d, 1H) ; 7.25 (d, 1H) ; 8.06 (m, 1H) ; 8.41 (d, 1H).

MS-ESI : 444 [MH]⁺

Elemental analysis	Found	C 59.14	H 6.44	N 9.08
20 C ₂₃ H ₂₉ N ₃ O ₆ , 1.2 H ₂ O	Requires	C 59.39	H 6.80	N 9.03

The starting material was prepared as follows:



25 A solution of (5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine [Collect. Czech. Chem. Commun. 1999, 64(2), 217-228] (0.329 g ; 1.36 mmol),

- 34 -

EDCI (0.230 g ; 1.2 mmol); DMAP (0.025 g, 0.2 mmol) and 2[2-(tert-butoxycarbonylamino) acetyl amino] acetic acid (0.189 g ; 1.2 mmol) in dichloromethane was stirred under argon atmosphere overnight. The resulting precipitate was filtered and washed with ether to give N-

5 [(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo [a,c] cyclohepten-5-yl]-2-[2-

Yield : 65 %.

¹H NMR (DMSO-d₆) : 1.33 (s, 9H) ; 1.94-2.24 (m, 3H) ; 2.97-3.08 (m, 1H) ; 3.35 (s, 3H) ; 3.56 (t, 3H) ; 3.71-3.77 (m, 1H) ; 3.75 (s, 3H) ; 3.78 (s, 3H) ; 3.80 (s, 3H) ; 4.48-4.59 (m, 1H) ; 6.79 (s, 1H) ; 6.87 (dd, 1H) ; 6.93 (d, 1H) ; 7.14 (t, 1H) ; 7.25 (d, 1H) ; 8.17 (t, 1H) ; 8.21 (d,


10 1H).

MS-ESI : 544 [MH]⁺

Example 2

4-Oxo-4-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]amino]butyl disodium phosphate

15




A solution of N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-4-[di(tert-butoxy)phosphoryloxy]butanamide (0.529g; 0.892 mmol) in a mixture of (12N) HCl (5 ml) and dioxan (25 ml) was stirred under argon atmosphere for 4 hours. After evaporation of the dioxan, the pH was adjusted at 7.2 with sodium hydroxide solution (2N) and the residue purified on HP20SS resin eluting with a 0-40 % gradient of methanol/water to give the title compound after freeze drying.

25 Yield : 75 %

¹H NMR (DMSO-d₆) : 1.71-2.36 (m, 7H) ; 2.58 partially obscured by DMSO peak (m, 1H) ; 3.49 (s, 3H) ; 3.78 -3.85 (m, 11H) ; 5.20 (dd, 1H) ; 5.00 (s, 1H) ; 6.77 (s, 1H) ; 6.88 (dd, 1H) ; 6.91 (d, 1H) ; 6.26 (d, 1H).

- 35 -

The starting material was prepared as follows:




N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-4-[di(tert-butoxy)phosphoryloxy]butanamide was prepared using a similar method to that of Example 1 by reacting (5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine with 4-[di(tert-butoxy)phosphoryloxy]butanoic acid.

Yield : 89 %

¹H NMR (DMSO-d₆): 1.40 (s, 18H) ; 1.80 (t, 2H) ; 1.82-1.94 (m, 1H) ; 2.00-2.20 (m, 2H) ; 2.23-2.33 (m, 2H) ; 2.52-2.58 (m, 1H) ; 3.48 (s, 3H) ; 3.78 (s, 3H) ; 3.80-3.85 (m, 8H) ; 4.50-4.59 (m, 1H) ; 6.78 (s, 1H) ; 6.89 (dd, 1H) ; 6.90 (d, 1H) ; 7.26 (d, 1H) ; 8.42 (d, 1H).

Example 3

N-[N-[2-(Imidazol-1-yl)ethyl]carbamoyl]-5(S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine



A solution of (5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine (0.263 g ; 0.8 mmol), 4-nitrophenol chloroformate (0.177 g ; 0.88 mmol) and triethylamine (0.123 ml ; 0.88 mmol) in dichloromethane was stirred under argon atmosphere for 1 hour. 2-(Imidazol-1-yl)ethylamine (0.145 ml ; 1.2 mmol) was added. After stirring for 2 hours, the mixture was evaporated to dryness and the residue purified on reverse phase silica

- 36 -

eluting with a 40-60 % gradient of methanol / ammonium carbonate buffer (2 g/l, pH 7) to give the title compound after evaporation and trituration in ether.

Yield : 52 %.

^1H NMR (DMSO- d_6) : 1.66-1.77 (m, 1H) ; 1.97-2.10 (m, 1H) ; 2.13-2.25 (m, 1H) ; 2.53

5 partially obscured by DMSO peak (m, 1H) ; 3.12-3.32 (m, 2H) ; 3.47 (s, 3H) ; 3.77 (s, 3H) ; 3.79 (s, 3H) ; 3.83 (s, 1H) ; 3.94 (t, 3H) ; 4.32-4.42 (m, 1H) ; 5.97 (t, 1H) ; 6.63 (d, 1H) ; 6.77 (s, 1H) ; 6.83-6.92 (m, 3H) ; 7.11 (s, 1H) ; 7.24 (d, 1H) ; 7.54 (s, 1H).

MS-ESI : 481 [MH] $^+$

Elemental analysis	Found	C 64.68	H 6.89	N 11.55
10 $\text{C}_{26}\text{H}_{32}\text{N}_4\text{O}_5$	Requires	C 64.98	H 6.71	N 11.66

Example 4

2-[N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamoyloxy]ethyl disodium phosphate

15



A solution of 2-[di-(benzyloxy)phosphoryloxy]ethyl N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamate (0.576 g ; 0.85 mmol) in solution in
 20 methanol (10 ml) and ethyl acetate (5 ml) was hydrogenated in the presence of 10 % C/Pd (0.165 mg) for 4 hours. After filtration on celite and evaporation, the residue was purified on HP20 SS resin eluting with a 0-80 % gradient of methanol/distilled water. The pH of the corresponding fractions was adjusted at 8 with aqueous sodium hydroxide solution (2N), after evaporation of the methanol. After freeze drying the title compound was obtained as a white
 25 solid.

Yield : 83 %


^1H NMR (DMSO- d_6 + TFA- d) : 1.85-1.97 (m, 1H) ; 1.98-2.09 (m, 1H) ; 2.13-2.27 (m, 1H) ; 2.42-2.52 (m, 1H) ; 3.48 (s, 3H) ; 3.79 (s, 3H) ; 3.80 (s, 3H) ; 3.84 (s, 3H) ; 3.98 (m, 2H) ;

- 37 -

4.03-4.18 (m, 2H) ; 4.04-4.17 (m, 2H) ; 4.24-4.35 (m, 1H) ; 6.77 (s, 1H) ; 6.89 (dd, 1H) ; 6.96 (d, 1H) ; 7.27 (d, 1H).

MS-ESI : 498 [MH]⁺

5 The starting material was prepared as follows:



4-Nitrophenyl chloroformate (1.01 g ; 5.04 mmol) was added at 0°C under argon atmosphere to a solution of 2-[di (benzyloxy)phosphoryloxy]ethanol (1.62 g ; 5.09 mmol) and triethylamine (0.7 ml ; 5 mmol) in dichloromethane (20 ml). The mixture was stirred at ambient temperature for 30 minutes, evaporated and purified by flash chromatography, eluting with petroleum ether / ethyl acetate (40/60) to give 2-[di(benzyloxy)phosphoryloxy]ethyl 4-nitrophenyl carbonate.

Yield : 45 %

¹H NMR (CDCl₃) : 4.21-4.30 (m, 2H) ; 4.41 (m, 2H) ; 5.01-5.15 (m, 4H) ; 7.29-7.42 (m, 12H) ; 8.25 (d, 2H).

A solution of (5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine (0.329 ; 1 mmol) and 2-[di-(benzyloxy)phosphoryloxy]ethyl 4-nitrophenyl carbonate (0.633 g ; 1.3 mmol) in acetonitrile (8 ml) was heated at 65°C, under argon atmosphere for 8 hours. After evaporation to dryness, the residue was purified by flash chromatography eluting with a 50-80 % gradient of ethyl acetate / petroleum ether to give 2-[di(benzyloxy)phosphoryloxy]ethyl N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamate.

Yield : 85 %


¹H NMR (DMSO-d₆) : 1.81-1.93 (m, 1H) ; 1.94-2.06 (m, 1H) ; 2.06-2.20 (m, 1H) ; 2.40-2.52 (m, 1H) ; 3.43 (s, 3H) ; 3.73 (s, 3H) ; 3.77 (s, 3H) ; 3.82 (s, 3H) ; 4.11 (m, 4H) ; 4.20-4.33 (m,

- 38 -

4H); 5.02 (d, 4H); 6.76 (s, 1H); 6.86 -dd, 1H); 6.93 (d, 1H) ; 7.25 (d, 1H) . 7.35 (s, 10H) ; 7.99 (d, 1H).

Example 5

5 2-Morpholinoethyl *N*-[(5*S*)-3,9,10,11-tetramethoxy-6,7-dihydro-5*H*-dibenzo[a,c]cyclohepten-5-yl]carbamate



A solution of (5*S*)-3,9,10,11-tetramethoxy-6,7-dihydro-5*H*-dibenzo[a,c]cyclohepten-5-amine [Collect. Czech. Chem. Commun. 1999, 64(2), 217-228] (0.263 g ; 0.8 mmol),
 10 4-nitrophenylchloroformate (0.177 g ; 0.88 mmol) and triethylamine (0.123 ml ; 0.88 mmol) in acetonitrile (5 ml) was stirred under argon atmosphere for 2 hours at ambient temperature ;
 4-(2-hydroxyethyl)morpholine (0.145 ml ; 1.2 mmol) in solution in acetonitrile (2 ml) was then added to the above solution. The mixture was heated at 60°C overnight. After evaporation to dryness, the residue was purified by flash chromatography, eluted with
 15 ethanol/dichloromethane (4/96) to give the title compound.

Yield : 64 %

¹H NMR Spectrum (DMSO-*d*₆ + AcO-*d*₄) : 1.82-2.31 (m, 3H) ; 2.44 (m, 4H) ; 2.49 (m, 2H) ;
 2.57 partially obscured by DMSO peak (m, 1H) ; 3.47 (s, 3H) ; 3.56 (m, 4H) ; 3.78 (s, 3H) ;
 3.79 (s, 3H) ; 3.83 (s, 3H) ; 4.03 (m, 2H) ; 4.17-4.33 (m, 1H) ; 6.76 (s, 1H) ; 6.88 (dd, 1H) ;
 20 6.93 (d, 1H) ; 7.26 (d, 1H) ; 7.86 (d, 1H).


MS-ESI : 487 [MH]⁺

Elemental analysis :

C₂₆H₃₄N₂O₇ · 0.3 H₂O

Found	C 63.38	H 7.04	N 5.74
Requires	C 63.48	H 7.09	N 5.69

- 39 -

Example 6**3-(1-Methylpiperazin-4-yl)propyl N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl] carbamate**

5

Using a similar procedure to that described for Example 5, (5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine was reacted with 4-(3-hydroxypropyl)-1-methylpiperazine to give the title compound.


Yield : 40 %.

¹H NMR (DMSO-d₆) : 1.62-2.44 (m, 20H) ; 2.54 partially obscured by DMSO peak (m, 1H) ; 3.46 (s, 3H) ; 3.77 (s, 3H) ; 3.78 (s, 3H) ; 3.82 (s, 3H) ; 6.78 (s, 1H) ; 6.89 (dd, 1H) ; 6.93 (d, 1H) ; 7.27 (d, 1H) ; 7.80 (d, 1H).

MS-ESI : 514 [MH]⁺

Elemental analysis : Found C 65.42 H 7.54 N 8.18

15 C₂₈H₃₉N₃O₆ Requires C 65.48 H 7.65 N 8.18

Example 7**2-(1-Acetylpiperazin-4-yl)ethyl-N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl] carbamate**

20

A solution of 2-(piperazin-4-yl)ethyl-N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamate (0.255 g ; 0.525 mmol), acetyl chloride (0.038 ml ; 0.53 mmol) and triethylamine (0.073 ml ; 0.525 mmol) in dichloromethane (10 ml) was stirred at ambient temperature under argon atmosphere for 2 hours. After evaporation to

- 40 -

dryness, the residue was purified by flash chromatography, eluting with dichloromethane/ethanol (93/7) to give the title compound.

Yield : 90 %

^1H NMR (DMSO- d_6) : 1.81-2.32 (m, 3H) ; 1.97 (s, 3H) ; 2.33 (m, 2H) ; 2.40 (m, 2H) ; 2.47


5 partially obscured by DMSO peak (m, 2H) ; 2.58 partially obscured by DMSO peak (m, 1H) ; 3.38 (m, 4H) ; 3.46 (s, 3H) ; 3.77 (m, 3H) ; 3.80 (s, 3H) ; 3.82 (s, 3H) ; 3.92-4.10 (m, 2H) ; 4.20-4.30 (m, 1H) ; 6.77 (s, 1H) ; 6.88 (dd, 1H) ; 6.92 (d, 1H) ; 7.25 (d, 1H) ; 7.87 (d, 1H).

MS-ESI : 528 $[\text{MH}]^+$

Elemental analysis :

	Found	C 63.21	H 7.30	N 7.86
10 $\text{C}_{28}\text{H}_{37}\text{N}_3\text{O}_7$	Requires	C 63.52	H 7.08	N 7.94

The starting material was prepared as follows :



2-(1-tert-Butoxycarbonyl)piperazin-4-yl)ethyl-N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-
15 5H-dibenzo[a,c]cyclohepten-5-yl]carbamate was prepared using a similar method to that described for Example 1, but using 2-[1-(tert-butoxycarbonyl)piperazin-4-yl]ethanol.

Yield : 75 %

^1H NMR (DMSO- d_6) : 1.78-1.94 (m, 1H) ; 1.95-2.07 (m, 1H) ; 2.10-2.23 (m, 1H) ; 2.30 (m, 4H) ; 2.38-2.53 (m, 3H) ; 2.65 (t, 2H) ; 3.46 (s, 3H) ; 3.77 (s, 3H) ; 3.78 (s, 3H) ; 3.82 (s, 3H) ;
20 3.99 (t, 2H) ; 4.20-4.32 (m, 1H) ; 6.77 (s, 1H) ; 6.88 (dd, 1H) ; 6.92 (d, 1H) ; 7.25 (d, 1H) ; 7.86 (d, 1H).

2-(1-tert-Butoxycarbonyl)piperazin-4-yl)ethyl-N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamate (0.617 g ; 1.05 mmol) in dichloromethane (10
25 ml) was treated with TFA (5 ml) at ambient temperature for 1 hour. After evaporation to dryness, the residue was neutralised to pH 8 with sodium hydroxide solution and purified on reverse phase silica eluting with a gradient of 30 - 40 % methanol / ammonium carbonate

- 41 -


buffer (2 g/l, pH 7) to give 2-(piperazin-4-yl) ethyl- N-[(5S)-3,9,10,11-tetramethoxy-6-7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl] carbamate.

Yield : 60 %

¹H NMR (DMSO-d₆) : 1.39 (s, 9H) ; 1.81-1.94 (m, 1H) ; 1.95-2.07 (m, 1H) ; 2.09-2.27 (m, 1H) ; 2.34 (m, 4H) ; 2.52-2.64 (m, 1H) ; 3.28 (m, 2H) ; 3.36 (s, 3H) ; 3.46 (s, 3H) ; 3.77 (s, 3H) ; 3.82 (s, 3H) ; 3.94-4.09 (m, 2H) ; 4.20-4.30 (m, 1H) ; 6.77 (s, 1H) ; 6.87 (dd, 1H) ; 6.92 (d, 1H) ; 7.25 (d, 1H) ; 7.86 (d, 1H).

Example 8

10 N-[(5S)-3,9,10,11-Tetramethoxy-6-7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-4-(1-methylpiperazin-4-yl)-4-oxobutan-1-amide



A solution of 4-(1-methylpiperazin-4-yl)-4-oxo butanoic acid (0.356 g ; 1.78 mmol), EDCI (0.367 g ; 1.78 mmol) and DMAP (0.05 g ; 0.41 mmol) in dichloromethane (30 ml) was stirred for 35 minutes under argon atmosphere. (5S)-3,9,10,11-Tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine 0.45 g ; 1.37 mmol) was then added and the mixture stirred at ambient temperature overnight. After evaporation of the solvent, the residue was purified by flash chromatography, eluting with dichloromethane/ethanol (95/5) to give after evaporation and trituration in pentane, the title compound as a white solid.

Yield : 60 %

¹H NMR (DMSO-d₆) : 1.85-1.96 (m, 1H) ; 2.01-2.15 (m, 1H) ; 2.16 (s, 3H) ; 2.22 (t, 2H) ; 2.26 (t, 2H) ; 2.33-2.42 (m, 1H) ; 2.47-2.53 (m, 1H) ; 3.35-3.46 (m, 4H) ; 3.46 (s, 3H) ; 3.79 (s, 3H) ; 3.82 (s, 3H) ; 3.84 (s, 3H) ; 4.44-4.56 (m, 1H) . 6.79 (s, 1H) ; 6.86 (dd, 1H) ; 6.98 (d, 1H) ; 7.25 (d, 1H) ; 8.40 (d, 1H).

MS-ESI : 512 [MH]⁺

Elemental analysis


C₂₈H₃₇N₃O₆

Found

Requires

C 65.51 H 7.40 N 8.19

C 65.73 H 7.29 N 8.21

Example 9**3-(1-Acetylpiperazin-4-yl) propyl-N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamate**

A solution of (5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine (0.329 g ; 1 mmol) and 3-(4-acetylpiperazino)propyl 4-nitrophenylcarbonate (0.456 g; 1.3 mmol) in acetonitrile (8 ml) was heated under argon atmosphere at 70°C for 6 hours. After evaporation to dryness, the residue was purified by flash chromatography eluting with dichloromethane/ethanol (93/7) to give the title compound.


Yield : 80 %

¹H NMR (DMSO-d₆) : 1.62-2.51 (m, 12H) ; 1.97 (s, 3H) ; 3.32-3.44 (m, 4H) ; 3.46 (s, 3H) ; 3.77 (s, 3H) ; 3.78 (s, 3H) ; 3.82 (s, 3H) ; 3.87-4.01 (m, 2H) ; 4.19-4.31 (m, 1H) ; 6.77 (s, 1H) ; 6.88 (dd, 1H) ; 6.92 (d, 1H) ; 7.25 (d, 1H) ; 7.80 (d, 1H).

15 MS-ESI : 542 [MH]⁺

Elemental analysis	Found	C 63.48	H 7.25	N 7.72
C ₂₉ H ₃₉ N ₃ O ₇ , 0.4 H ₂ O	Requires	C 63.46	H 7.31	N 7.66

The starting material was prepared as follows :




4-Nitrophenyl chloroformate (0.733 g ; 3.63 mmol) was added to a solution of 3-(4-acetylpiperazin-1-yl) propanol [Synthesis (1997), 6, 643-648] (0.645 g ; 3.46 mmol) and triethylamine (0.51 ml ; 3.36 mmol) in dichloromethane (7 ml) under argon atmosphere at 0°C. The mixture was stirred at ambient temperature for 1 hour, evaporated to dryness and purified by flash chromatography, eluting with dichloromethane/ethanol (95/5) to give 3-(4-acetylpiperazino)propyl 4-nitrophenyl carbonate.

- 43 -

^1H NMR (CDCl_3) : 1.96 (m, 2H) ; 2.09 (s, 3H) ; 2.39-2.48 (m, 4H) ; 2.51 (t, 2H) ; 3.47 (t, 3H) ; 3.63 (t, 2H) ; 3.68-3.78 (m, 2H) ; 4.38 (t, 2H) ; 7.39 (d, 2H) ; 8.29 (d, 2H).

Example 10

5 4-Morpholino-4-oxobutyl-N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo [a-c]cyclohepten-5-yl]carbamate



The compound was prepared using a similar method to that of Example 9, but replacing 3-(4-acetylpiperazino)propyl 4-nitrophenyl carbonate by 4-morpholino-4-oxobutyl 4-

10 nitrophenylcarbonate.

Yield : 55 %.

^1H NMR ($\text{DMSO}-d_6$) : 1.71-1.81 (m, 2H) ; 1.82-1.94 (m, 1H) ; 1.95-2.07 (s, 1H) ; 2.11-2.24 (s, 1H) ; 2.34 (t, 2H) ; 2.46 (m, 1H) ; 3.31-3.44 (m, 4H) ; 3.45 (s, 3H) ; 3.52 (m, 4H) ; 3.77 (s, 3H) ; 3.78 (s, 3H) ; 3.82 (s, 3H) ; 3.86-3.98 (m, 2H) ; 4.20-4.32 (m, 1H) ; 6.77 (s, 1H) ; 6.88 (dd, 1H) ; 6.92 (d, 1H) ; 7.25 (d, 1H) ; 7.80 (d, 1H).

MS-ESI : 529 $[\text{MH}]^+$


Elemental analysis	Found	C 62.81	H 6.95	N 5.27
$\text{C}_{28}\text{H}_{36}\text{N}_2\text{O}_8, 0.3 \text{ H}_2\text{O}$	Requires	C 62.98	H 6.91	N 5.25

20 The starting material was prepared using a similar method to that of example 9, starting from 4-morpholino-4-oxobutyl 4-nitrophenyl carbonate.

Yield : 92 %

^1H NMR (CDCl_3) : 2.15 (m, 2H) ; 2.50 (t, 2H) ; 3.46-3.53 (m, 2H) ; 3.51-3.75 (m, 6H) ; 3.38 (t, 2H) ; 7.33 (d, 2H) ; 8.29 (d, 2H).

- 44 -

Example 11**4-(1-Methylpiperazin-4-yl)-4-oxobutyl-N-[(5S)-3,9,10, 11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cylcohepten-5-yl]carbamate**

The title compound was prepared using a similar method to that of Example 9, but replacing 3-(4-acetylpiperazino)propyl 4-nitrophenyl carbonate by 4-methylpiperazin-1-yl)-4-oxobutyl 4-nitrophenyl carbonate.

10 Yield : 65%

^1H NMR ($\text{DMSO}-d_6$) : 1.75 (m, 2H) ; 1.81-2.07 (m, 2H) ; 2.08-2.40 (m, 7H) ; 2.15 (s, 3H) ; 2.50-2.60 (m, 1H) ; 3.22-3.56 (m, 4H) ; 3.45 (s, 3H) ; 3.77 (s, 3H) ; 3.78 (s, 3H) ; 3.82 (s, 3H) ; 3.82-3.99 (m, 2H) ; 4.12-4.32 (m, 1H) ; 6.76 (s, 1H) ; 6.87 (dd, 1H) ; 6.92 (d, 1H) ; 7.25 (d, 1H) ; 7.80 (d, 1H).

15 MS-ESI : 542 $[\text{MH}]^+$

Elemental analysis	Found	C 63.38	H 7.58	N 7.64
$\text{C}_{29}\text{H}_{39}\text{N}_3\text{O}_7, 0.4 \text{ H}_2\text{O}$	Requires	C 63.46	H 7.31	N 7.66


The starting material was prepared using a similar method to that of Example 9, from 4-(4-methylpiperazin-1-yl)-4-oxobutanol.

Yield : 65 %.

^1H NMR (CDCl_3) : 2.08-2.19 (m, 2H) ; 2.32 (s, 3H) ; 2.35-2.46 (m, 4H) ; 2.49 (t, 2H) ; 3.51 (t, 2H) ; 2.66 (t, 2H) ; 4.38 (t, 2H) ; 7.39 (d, 2H) ; 8.29 (d, 2H).

Claims

1. A compound of the formula (I):



(I)

wherein:

R^1 , R^2 and R^3 are each independently hydroxy, phosphoryloxy ($-\text{OPO}_3\text{H}_2$), C_{1-4} alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R^1 , R^2 and R^3 are C_{1-4} alkoxy;

A is $-\text{CO}-$, $-\text{C}(\text{O})\text{O}-$, $-\text{CON}(\text{R}^8)-$, $-\text{SO}_2-$ or $-\text{SO}_2\text{N}(\text{R}^8)-$ (wherein R^8 is hydrogen, C_{1-4} alkyl, C_{1-3} alkoxy C_{1-3} alkyl, amino C_{1-3} alkyl or hydroxy C_{1-3} alkyl);

a is an integer from 1 to 4 inclusive;

R^a and R^b are independently selected from hydrogen, hydroxy and amino;

B is $-\text{O}-$, $-\text{CO}-$, $-\text{N}(\text{R}^9)\text{CO}-$, $-\text{CON}(\text{R}^9)-$, $-\text{C}(\text{O})\text{O}-$, $-\text{N}(\text{R}^9)-$, $-\text{N}(\text{R}^9)\text{C}(\text{O})\text{O}-$, $-\text{N}(\text{R}^9)\text{CON}(\text{R}^{10})-$, $-\text{N}(\text{R}^9)\text{SO}_2-$, $-\text{SO}_2\text{N}(\text{R}^9)-$ or a direct single bond (wherein R^9 and R^{10} are independently selected from hydrogen, C_{1-4} alkyl, C_{1-3} alkoxy C_{1-3} alkyl, amino C_{1-3} alkyl and hydroxy C_{1-3} alkyl);

b is 0 or an integer from 1 to 4 inclusive, (provided that when b is 0, B is a single direct bond);

D is carboxy, sulfo, tetrazolyl, imidazolyl, phosphoryloxy, hydroxy, amino,

$\text{N}-(\text{C}_{1-4}\text{alkyl})\text{amino}$, $\text{N,N-di}(\text{C}_{1-3}\text{alkyl})\text{amino}$ or of the formula $-\text{Y}^1-(\text{CH}_2)_c\text{R}^{11}$ or $-\text{NHCH}(\text{R}^{12})\text{COOH}$; [wherein Y^1 is a direct single bond, $-\text{O}-$, $-\text{C}(\text{O})-$, $-\text{N}(\text{R}^{13})-$, $-\text{N}(\text{R}^{13})\text{C}(\text{O})-$ or $-\text{C}(\text{O})\text{N}(\text{R}^{13})-$ (wherein R^{13} is hydrogen, C_{1-4} alkyl,

C_{1-3} alkoxy C_{2-3} alkyl, amino C_{2-3} alkyl or hydroxy C_{2-3} alkyl); c is 0 or an integer from 1 to 4 inclusive; R^{11} is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from

- 46 -

O, S and N, or a 5-6-membered unsaturated or partially unsaturated heteroaryl group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O, S and N, which heterocyclic group or heteroaryl group may bear 1 or 2 substituents selected from:

- 5 oxo, hydroxy, halogeno, C₁₋₄alkyl, C₂₋₄alkanoyl, carbamoyl,
 N-(C₁₋₄alkyl)carbamoyl, N,N-di-(C₁₋₄alkyl)carbamoyl, hydroxyC₁₋₄alkyl,
 C₁₋₄alkoxy, cyanoC₁₋₃alkyl, carbamoylC₁₋₃alkyl, carboxyC₁₋₄alkyl, aminoC₁₋₄alkyl,
 N-C₁₋₄alkylaminoC₁₋₄alkyl, di-N,N-(C₁₋₄alkyl)aminoC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl,
 C₁₋₄alkylsulphonylC₁₋₄alkyl and R¹⁴ (wherein R¹⁴ is a 5-6-membered saturated
 10 heterocyclic group (linked via carbon or nitrogen) containing 1 or 2 ring
 heteroatoms, selected independently from O, S and N, which heterocyclic group is
 optionally substituted by 1 or 2 substituents selected from:
 oxo, hydroxy, halogeno, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkoxy,
 C₁₋₄alkoxyC₁₋₄alkyl and C₁₋₄alkylsulphonylC₁₋₄alkyl);

15 R¹² is an amino acid side chain;

 R⁵ is C₁₋₄alkoxy;

 R⁴ and R⁶ are each independently selected from: hydrogen, fluoro, nitro, amino,

 N-C₁₋₄alkylamino, N,N-di-(C₁₋₄alkyl)amino, hydroxy, C₁₋₄alkoxy and C₁₋₄alkyl;

 R⁷ is hydrogen, C₁₋₄alkyl, C₁₋₃alkoxyC₁₋₃alkyl, aminoC₁₋₃alkyl or hydroxyC₁₋₃alkyl;

20 or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

2. A compound according to claim 1 where R¹, R² and R³ are all methoxy.
 or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

25 3 A compound according to claim 1 wherein:

 R¹, R², and R³ are all C₁₋₄alkoxy;

 R⁴ and R⁶ are independently selected from hydrogen, hydroxy, C₁₋₃alkoxy, and
 C₁₋₃alkyl;

 R⁵ is methoxy;

30 A is -CO-, -C(O)O- or -CONH-;


 a is 1, 2 or 3;

- 47 -

- B is -CO-, -NHCO-, -CONH-, -C(O)O-, -NH-, -NHC(O)O-, NHCONH- or a single direct bond;
- b is 0, 1 or 2;
- D is carboxy, sulpho, phosphoryloxy, hydroxy, amino, N-C₁₋₄ alkylamino, N,N-di(C₁₋₄ alkyl)amino or of the formula -Y¹(CH₂)_cR¹¹ (wherein Y¹ is -NHC(O)- or -C(O)NH-;
- 5 c is 1 or 2; R¹¹ is a 5-6-membered saturated heterocyclic group (linked via nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O and N, which heterocyclic group may bear 1 or 2 substituents selected from:
- C₁₋₄ alkyl, C₂₋₄alkanoyl, carbamoyl, cyanoC₁₋₃alkyl, hydroxyC₁₋₃alkyl,
- 10 carboxyC₁₋₃alkyl and aminoC₁₋₃alkyl);
- R⁷ is hydrogen;
- or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.
4. A compound according to claim 1 wherein:
- 15 R¹, R², and R³ are all methoxy;
- R⁴ and R⁶ are independently selected from hydrogen, hydroxy, methoxy and methyl;
- R⁵ is methoxy;
- A is -CO-, -C(O)O- or -CONH-;
- a is 2 or 3;
- 20 B is -CO-, -NHCO-, -CONH or a single direct bond;
- b is 0 or 1;
- D is carboxy, phosphoryloxy, hydroxy, amino, N-C₁₋₄ alkylamino, N,N-di(C₁₋₄ alkyl)amino or of the formula -Y¹(CH₂)_cR¹¹ (wherein Y¹ is -NHC(O)- or -C(O)NH-;
- c is 1 or 2; R¹¹ is piperazinyl, morpholinyl or piperidinyl, each of which is linked via
- 25 a ring nitrogen atom and each ring is optionally substituted by 1 or 2 substituents selected from:
- C₁₋₄alkyl, C₂₋₄alkanoyl, carbamoyl, cyanoC₁₋₃alkyl, hydroxyC₁₋₃alkyl,
- carboxyC₁₋₃alkyl and aminoC₁₋₃alkyl);
- R⁷ is hydrogen;
- 30 or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.

- 48 -

5. A compound of formula (II):



wherein a, b, A, B and D are as defined in claim 1;
or a pharmaceutically acceptable salt, solvate or prodrug thereof.

5

6. A compound according to claim 5 wherein:

A is -CO-, -C(O)O- or -CONH-;

a is 2 or 3;

B is -CO-, -NHCO-, -CONH or a single direct bond;

10

b is 0 or 1;


D is carboxy, phosphoryloxy, hydroxy, amino, N-C₁₋₄ alkylamino, N,N-di(C₁₋₄ alkyl)amino or of the formula -Y¹(CH₂)_cR¹¹ (wherein Y¹ is -NHC(O)- or -C(O)NH-; c is 1 or 2; R¹¹ is piperazinyl, morpholinyl or piperidinyl, each of which is linked via a ring nitrogen atom and each ring is optionally substituted by 1 or 2 substituents selected from:

15

C₁₋₄alkyl, C₂₋₄alkanoyl, carbamoyl, cyanoC₁₋₃alkyl, hydroxyC₁₋₃alkyl, carboxyC₁₋₃alkyl and aminoC₁₋₃alkyl);

or a pharmaceutically acceptable salt, solvate or prodrug thereof.

- 20 7. A compound of formula (III):



(III)

wherein:

R^1 , R^2 and R^3 are each independently hydroxy, phosphoryloxy ($-\text{OPO}_3\text{H}_2$), C_{1-4} alkoxy or an in vivo hydrolysable ester of hydroxy, with the proviso that at least 2 of R^1 , R^2 and R^3 are C_{1-4} alkoxy;

5 A is $-\text{CO}-$, $-\text{C}(\text{O})\text{O}-$, $-\text{CON}(\text{R}^8)-$, $-\text{SO}_2-$ or $-\text{SO}_2\text{N}(\text{R}^8)-$ (wherein R^8 is hydrogen, C_{1-4} alkyl, C_{1-3} alkoxy C_{2-3} alkyl, amino C_{2-3} alkyl or hydroxy C_{2-3} alkyl);

a is an integer from 1 to 4 inclusive;

R^a and R^b are independently selected from hydrogen, hydroxy and amino;

10 B is $-\text{O}-$, $-\text{CO}-$, $-\text{N}(\text{R}^9)\text{CO}-$, $-\text{CON}(\text{R}^9)-$, $-\text{C}(\text{O})\text{O}-$, $-\text{N}(\text{R}^9)-$, $-\text{N}(\text{R}^9)\text{C}(\text{O})\text{O}-$, $-\text{N}(\text{R}^9)\text{CON}(\text{R}^{10})-$, $-\text{N}(\text{R}^9)\text{SO}_2-$, $-\text{SO}_2\text{N}(\text{R}^9)-$ or a direct single bond (wherein R^9 and R^{10} are independently selected from hydrogen, C_{1-4} alkyl, C_{1-3} alkoxy C_{2-3} alkyl, amino C_{2-3} alkyl and hydroxy C_{2-3} alkyl);

b is 0 or an integer from 1 to 4 inclusive;

15 D is a 5-6-membered saturated heterocyclic group (linked via carbon or nitrogen) containing 1 or 2 ring heteroatoms, selected independently from O and N, which heterocyclic group may bear 1 or 2 substituents selected from:

oxo, hydroxy, halogeno, C_{1-4} alkyl, C_{2-4} alkanoyl, carbamoyl,

$\text{N}-(\text{C}_{1-4}\text{alkyl})\text{carbamoyl}$, $\text{N,N-di}-(\text{C}_{1-4}\text{alkyl})\text{carbamoyl}$, hydroxy $\text{C}_{1-4}\text{alkyl}$,

C_{1-4} alkoxy, cyano $\text{C}_{1-3}\text{alkyl}$, carbamoyl $\text{C}_{1-3}\text{alkyl}$, carboxy $\text{C}_{1-4}\text{alkyl}$, amino $\text{C}_{1-4}\text{alkyl}$,

20 $\text{N-C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkyl}$, di- $\text{N,N}-(\text{C}_{1-4}\text{alkyl})\text{aminoC}_{1-4}\text{alkyl}$, C_{1-4} alkoxy $\text{C}_{1-4}\text{alkyl}$,

$\text{C}_{1-4}\text{alkylsulphonylC}_{1-4}\text{alkyl}$ and R^{14} (wherein R^{14} is a 5-6-membered saturated

heterocyclic group (linked via carbon or nitrogen) containing 1 or 2 ring

heteroatoms, selected independently from O and N, which heterocyclic group is

optionally substituted by 1 or 2 substituents selected from:

25 oxo, hydroxy, halogeno, $\text{C}_{1-4}\text{alkyl}$, hydroxy $\text{C}_{1-4}\text{alkyl}$, C_{1-4} alkoxy,

C_{1-4} alkoxy $\text{C}_{1-4}\text{alkyl}$ and $\text{C}_{1-4}\text{alkylsulphonylC}_{1-4}\text{alkyl}$);

R^5 is C_{1-4} alkoxy;

R^4 and R^6 are each independently selected from:

hydrogen, halogeno, nitro, amino, $\text{N-C}_{1-4}\text{alkylamino}$, $\text{N,N-di}-(\text{C}_{1-4}\text{alkyl})\text{amino}$,

30 hydroxy, C_{1-4} alkoxy and $\text{C}_{1-4}\text{alkyl}$;

R^7 is hydrogen, $\text{C}_{1-4}\text{alkyl}$, C_{1-3} alkoxy $\text{C}_{1-3}\text{alkyl}$, amino $\text{C}_{1-3}\text{alkyl}$ or hydroxy $\text{C}_{1-3}\text{alkyl}$;


or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

- 50 -

8. A compound according to claim 7 wherein:
R¹, R², and R³ are all C₁₋₄alkoxy;
R⁴ and R⁶ are independently selected from hydrogen, hydroxy, C₁₋₃ alkoxy, and
5 C₁₋₃alkyl;
R⁵ is methoxy;
A is -CO-, -C(O)O- or -CONH-;
a is 1, 2 or 3;
B is -CO-, -NHCO-, -CONH-, -C(O)O-, -NH-, -NHC(O)O-, NHCONH- or a single
10 direct bond;
b is 0, 1 or 2;
D is piperazinyl or morpholinyl or piperidinyl, each ring being optionally substituted by
1 or 2 substituents selected from C₁₋₄alkyl, C₂₋₄alkanoyl, carbamoyl, cyanoC₁₋₃alkyl,
hydroxyC₁₋₃alkyl, carboxyC₁₋₃alkyl and aminoC₁₋₃alkyl;
15 R⁷ is hydrogen;
or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.
9. A compound according to claim 7 wherein:
R¹, R², and R³ are all methoxy;
20 R⁴ and R⁶ are independently selected from hydrogen, hydroxy, methoxy and methyl;
R⁵ is methoxy;
A is -CO-, -C(O)O- or -CONH-;
a is 2 or 3;
B is -CO-, -NHCO-, -CONH or a single direct bond;
25 b is 0 or 1;
D is piperazino or morpholino, each ring being optionally substituted by 1 or 2
substituents selected from methyl, ethyl, acetyl, propionyl, carbamoyl and 2-
hydroxyethyl;
R⁷ is hydrogen;
30 or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.

- 51 -

10. A compound according to claim 7 wherein:



wherein a, b, A, B and D are as hereinabove defined in claim 7;
or a pharmaceutically-acceptable salt, solvate or pro-drug thereof.

5

11. A compound according to claim 10 wherein:

A is -CO-, -C(O)O- or -CONH-;

a is 2 or 3;

B is -CO-, -NHCO-, -CONH or a single direct bond;

10 b is 0 or 1;

D is piperazino or morpholino, each ring being optionally substituted by 1 or 2
substituents selected from methyl, ethyl, acetyl, propionyl, carbamoyl and 2-
hydroxyethyl;

or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

15

12. A compound according to claim 10 wherein:

A is -CO-, -C(O)O- or -CONH-;

a is 2 or 3;

B is -CO-, -NHCO-, -CONH or a single direct bond;

20 b is 0 or 1;

D is morpholino, 4-methylpiperazin-1-yl or 4-acetylpiperazin-1-yl;

or a pharmaceutically acceptable salt, solvate or pro-drug thereof.

13. A compound selected from:

25 N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-2-[2-
aminoacetyl]amino]acetamide;


4-oxo-4-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-
yl]amino]butyl disodium phosphate;

- 52 -

- N-[N-[2-(imidazol-1-yl)ethyl]carbamoyl]-5(S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine; and
- 2-[N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamoxyloxy]ethyl disodium phosphate;
- 5 2-morpholinoethyl N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamate;
- 3-(1-methylpiperazin-4-yl)propyl N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl] carbamate;
- 10 N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-2-[2-aminoacetylamino]acetamide;
- 2-(1-acetylpiperazin-4-yl)ethyl-N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl] carbamate;
- N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]-4-(1-methylpiperazin-4-yl)-4-oxobutan-1-amide;
- 15 4-oxo-4-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]amino]butyl disodium phosphate;
- N-[N-[2-(imidazol-1-yl)ethyl]carbamoyl]-5(S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-ylamine;
- 3-(1-acetylpiperazin-4-yl) propyl-N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamate;
- 20 N-1-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamoxyloxy]ethyl disodiumphosphate;
- 4-morpholino-4-oxobutyl-N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamate; and
- 25 4-(1-methylpiperazin-4-yl)-4-oxobutyl-N-[(5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-5-yl]carbamate;
- and pharmaceutically-acceptable salts, solvates or pro-drugs thereof.
14. A pharmaceutical composition comprising a compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt, solvate or pro-drug thereof, in association with a pharmaceutically acceptable carrier.
- 30


- 53 -

15. The use of a compound according any one claims 1 to 13, or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, in the manufacture of a medicament for use in the production of a vascular damaging effect in a warm-blooded animal.
- 5 16. The use of a compound according to any one of claim 1 to 13 or pharmaceutically-acceptable salt, solvate or pro-drug thereof in the manufacture of a medicament for administration in divided doses for use in the production of a vascular damaging effect in a warm-blooded animal.
- 10 17. A process for preparing a compound of the formula (I), or a compound of the formula (I) wherein at least 1 functional group is protected, wherein $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, A, B, D, a, b$ and c are as defined in claim 1, comprising:
- a) reacting a compound of the formula (X)



15

with a compound of the formula (XI):



wherein L^1 is a leaving group; or

- 20 b) converting one compound of the formula (I) into another compound of the formula (I);
- c) when a phosphoryloxy group is desired, reacting the corresponding hydroxy compound with a phosphoramidite;
- wherein any functional groups are optionally protected.
- 25 and thereafter if necessary:
- i) converting a compound of formula (I) into another compound of formula (I);
- ii) removing any protecting groups;

- 54 -

iii) forming a pharmaceutically acceptable salt, solvate or pro-drug thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PL/GB 01/02964

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D295/185 A61K31/495 A61P35/00 C07K5/062 C07F9/09
C07D295/088 C07C217/74 C07D233/61

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D C07K C07F C07C A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 02166 A (ANGIOGENE PHARM LTD ;DOUGHERTY GRAEME (GB)) 21 January 1999 (1999-01-21) page 15 -page 21; claims	1,5,7, 10,13-17

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

18 September 2001

Date of mailing of the international search report

26/09/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Sánchez García, J.M.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/02964

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9902166	A	21-01-1999	AU 8231198 A	08-02-1999
			BR 9810681 A	15-08-2000
			CN 1262624 T	09-08-2000
			EP 1001785 A1	24-05-2000
			WO 9902166 A1	21-01-1999
			HU 0002493 A2	28-08-2001
			NO 20000077 A	07-01-2000
			PL 337926 A1	11-09-2000
			SK 132000 A3	11-12-2000
			TR 9903149 T2	21-09-2000
